image
imagewidth (px) 230
933
| latex
stringlengths 184
5.27k
| filename
stringlengths 17
19
|
|---|---|---|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Scale} & \multicolumn{4}{|l|}{\textbf{Self-report}} & \multicolumn{4}{|l|}{\textbf{Proxy-report}} \\
\hline
& \textbf{N} & \textbf{Mean (sd)} & \textbf{df} & \textbf{F} & \textbf{N} & \textbf{Mean (sd)} & \textbf{df} & \textbf{F} \\
\hline
Total Score & & & 4,1393 & 23.84 & & & 4,965 & 41.07 \\
\hline
Asthma & 99 & 75.31(16.90) *** & & & 74 & 71.79(17.53)*** \\
\hline
Diabetes & 124 & 82.46(12.76) & & & 103 & 77.54(12.21) *** \\
\hline
Cancer & 66 & 75.68(15.40) *** & & & 61 & 70.96(17.06) *** \\
\hline
IBD & 76 & 74.18(14.66) *** & & & 67 & 72.65(17.62) *** \\
\hline
Healthy & 1033 & 83.89(11.84) & & & 665 & 84.61(11.19) \\
\hline
Physical Health & & & 4,1392 & 41.60 & & & 4,964 & 46.87 \\
\hline
Asthma & 99 & 76.14(19.10)*** & & & 75 & 73.36(20.60) *** \\
\hline
Diabetes & 124 & 84.75(13.65)** & & & 103 & 82.97(13.67) *** \\
\hline
Cancer & 66 & 78.10(17.64) *** & & & 61 & 75.04(18.79) *** \\
\hline
IBD & 76 & 75.08(18.21) *** & & & 67 & 71.54(21.98) *** \\
\hline
Healthy & 1032 & 88.51(11.62) & & & 665 & 89.06(12.27) \\
\hline
Psychosocial Health & & & 4,1393 & 14.53 & & & 4,964 & 28.16 \\
\hline
Asthma & 99 & 74.9(17.48) *** & & & 74 & 71.20(17.95) *** \\
\hline
Diabetes & 124 & 81.24(13.77) & & & 103 & 74.62(13.27) *** \\
\hline
Cancer & 66 & 74.37(15.85) *** & & & 61 & 68.83(17.92) *** \\
\hline
IBD & 76 & 73.64(14.35) *** & & & 67 & 73.21(17.43) *** \\
\hline
Healthy & 1033 & 81.84(13.21) & & & 664 & 82.21(12.67) \\
\hline
Emotional functioning & & & 4,1393 & 9.85 & & & 4,962 & 23.24 \\
\hline
Asthma & 99 & 70.66(20.06) *** & & & 74 & 67.23(21.20) *** \\
\hline
Diabetes & 124 & 78.85(18.28) & & & 102 & 66.01(17.80) *** \\
\hline
Cancer & 66 & 73.56(18.39) * & & & 61 & 68.36(18.04) *** \\
\hline
IBD & 76 & 68.11(18.90) *** & & & 67 & 67.26(21.41) *** \\
\hline
Healthy & 1033 & 78.49(17.94) & & & 663 & 78.28(15.54) \\
\hline
Social functioning & & & 4,1393 & 5.89 & & & 4,964 & 14.09 \\
\hline
Asthma & 99 & 81.76(21.35) *** & & & 74 & 76.96(21.69) *** \\
\hline
Diabetes & 124 & 89.15(13.91) & & & 103 & 85.28(15.98) \\
\hline
Cancer & 66 & 81.27(18.36) ** & & & 61 & 73.28(22.93) *** \\
\hline
IBD & 76 & 83.82(16.61) & & & 67 & 82.12(18.09) * \\
\hline
Healthy & 1033 & 87.65(16.46) & & & 664 & 86.82(15.42) \\
\hline
School functioning & & & 4,1386 & 14.12 & & & 4,960 & 26.90 \\
\hline
Asthma & 99 & 72.37(19.62) *** & & & 74 & 69.02(22.55) *** \\
\hline
Diabetes & 124 & 77.70(17.39) & & & 103 & 72.62(17.64) *** \\
\hline
Cancer & 63 & 67.38(20.36) *** & & & 58 & 63.45(21.71) *** \\
\hline
IBD & 73 & 69.52(17.28) *** & & & 66 & 70.46(20.95) *** \\
\hline
Healthy & 1032 & 78.87(15.89) & & & 664 & 81.52(16.09) \\
\hline
\end{tabular}}
\end{table}
|
PMC1079918_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Functional type} & \textbf{Fluffy tails (F$>$2)} & \textbf{No fluffy tails (F$<$2)} & \textbf{Positive rate} & \textbf{Negative rate} \\
\hline
Regulatory regions & 51 & 9 & 85 \% & 15 \% \\
\hline
Exons & 1 & 59 & 1.6 \% & 98.4 \% \\
\hline
Non-coding presumed non- regulatory & 10 & 50 & 16 \% & 84 \% \\
\hline
\end{tabular}}
\end{table}
|
PMC1127108_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Proliferation marker} & \textbf{rs} & \textbf{P} \\
\hline
Thymidylate synthase & 0.38 & $<$0.001 \\
\hline
Thymidine kinase 1 & 0.23 & $<$0.01 \\
\hline
Survivin & 0.22 & $<$0.01 \\
\hline
E2F & 0.22 & $<$0.01 \\
\hline
II$\alpha$ Topoisomerase & 0.19 & $<$0.05 \\
\hline
\end{tabular}}
\end{table}
|
PMC1175052_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{EM operation} & \textbf{Definition} \\
\hline
Overlap (x y) ❍ & x and y overlap if they have a part in common. \\
\hline
ι Disjoint (x y) & x and y are disjoint if they share no parts in common. \\
\hline
Binary product (x . y) & The parts that x and y share in common. \\
\hline
Difference (x - y) & The largest portion of x which has no part in common with y. \\
\hline
Binary sum (x + y) & The set consisting of individuals x and y. \\
\hline
\end{tabular}}
\end{table}
|
PMC1175956_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{Low A}} & \multicolumn{3}{|l|}{\textbf{Low B}} \\
\hline
& \textbf{Observed} & \textbf{RR} & \textbf{p-value} & \textbf{Observed} & \textbf{RR} & \textbf{p-value} \\
\hline
Not Adjusted & 440 & 0.81 & 0.004 & * & * & * \\
\hline
Adjusted for Urban/Rural Status & 440 & 0.81 & 0.002 & * & * & * \\
\hline
Adjusted for SES & * & * & * & 94 & 0.63 & 0.009 \\
\hline
Adjusted for SES \& Urban/Rural Status & * & * & * & 94 & 0.635 & 0.016 \\
\hline
\end{tabular}}
\end{table}
|
PMC1180846_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Group} & \textbf{Patient Number} & \textbf{Follow up (months)} & \textbf{Raised IOP} & \textbf{Stepwise deterioration in retinopathy grade at last FU (ETDRS)} \\
\hline
A & 1 & 15 & & 3 \\
\hline
& & 14 & & 1 \\
\hline
A & 2 & 6 & & 0 \\
\hline
& & 8 & Yes: 34 mmHg & 0 \\
\hline
A & 3 & 9 & & 0 \\
\hline
A & 4 & 10 & & 0 \\
\hline
& & 12 & Yes: 29 mm Hg & 1 \\
\hline
A & 5 & 11 & Yes: 31 mm Hg & 0 \\
\hline
A & 6 & 10 & & 1 \\
\hline
& & 7 & & 0 \\
\hline
A & 7 & 12 & & 0 \\
\hline
A & 8 & 5 & Yes: 24 mmHg & 1 \\
\hline
& & 5 & & 0 \\
\hline
A & 9 & 7 & & 1 \\
\hline
A & 10 & 6 & & 0 \\
\hline
B & 10 & 4 & & 0 \\
\hline
B & 11 & 8 & & 0 \\
\hline
B & 12 & 4 & & 0 \\
\hline
& & Mean FU = 8.5 \\
\hline
\end{tabular}}
\end{table}
|
PMC1183218_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Source} & \multicolumn{2}{|l|}{\textbf{dChip}} & \multicolumn{2}{|l|}{\textbf{MAS 5.0}} & \multicolumn{2}{|l|}{\textbf{RMA}} & \multicolumn{2}{|l|}{\textbf{GCRMA-EB}} \\
\hline
& \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD} \\
\hline
Biological variation & 0.431 & 0.304 & 0.292 & 0.300 & 0.393 & 0.306 & 0.310 & 0.292 \\
\hline
Labeling variation & 0.206 & 0.230 & 0.136 & 0.198 & 0.221 & 0.224 & 0.147 & 0.192 \\
\hline
Residual error & 0.363 & 0.274 & 0.572 & 0.311 & 0.386 & 0.272 & 0.543 & 0.298 \\
\hline
\end{tabular}}
\end{table}
|
PMC1232851_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Cont 3 M} & \textbf{Cont 6 M} & \textbf{Cont 11 M} & \textbf{Cont 21 M} & \textbf{Inulin 3 M} & \textbf{Inulin 6 M} & \textbf{Inulin 11 M} & \textbf{Inulin 21 M} & \textbf{inulin} & \textbf{age} & \textbf{interaction} \\
\hline
Plasma Ca, mg/L & 98 $\pm$ 4 & 98 $\pm$ 5 & 95 $\pm$ 6 & 100 $\pm$ 5 & 102 $\pm$ 5 & 99 $\pm$ 4 & 98 $\pm$ 3 & 100 $\pm$ 4 & 0.0601 & 0.0619 & NS \\
\hline
Tibia weight, mg dw & 480 $\pm$ 42 & 630 $\pm$ 80 & 717 $\pm$ 89 & 630 $\pm$ 93 & 489 $\pm$ 66 & 617 $\pm$ 66 & 841 $\pm$ 92 & 648 $\pm$ 47 & 0.042 & $<$0.0001 & 0.023 \\
\hline
Bone Ca, mg/g dw & 207 $\pm$ 21 & 214 $\pm$ 15 & 216 $\pm$ 15 & 215 $\pm$ 21 & 205 $\pm$ 13 & 215 $\pm$ 18 & 202 $\pm$ 14 & 228 $\pm$ 7 & NS & 0.018 & 0.0639 \\
\hline
Plasma Mg, mg/L & 17.9 $\pm$ 1.1 & 17.7 $\pm$ 1.1 & 17.2 $\pm$ 1.0 & 16.9 $\pm$ 1.3 & 17.6 $\pm$ 1.1 & 17.9 $\pm$ 1.3 & 18.2 $\pm$ 1.5 & 18.2 $\pm$ 1.7 & 0.0570 & NS & NS \\
\hline
Erythrocyte Mg, mg/L & 45.4 $\pm$ 3.8 & 44.2 $\pm$ 4.7 & 42.5 $\pm$ 3.4 & 43.4 $\pm$ 3.0 & 44.9 $\pm$ 4.9 & 43.8 $\pm$ 2.5 & 44.3 $\pm$ 3.6 & 43.8 $\pm$ 3.9 & NS & NS & NS \\
\hline
Bone Mg, mg/g dw & 3.92 $\pm$ 0.10 & 3.79 $\pm$ 0.08 & 3.72 $\pm$ 0.08 & 3.76 $\pm$ 0.08 & 3.91 $\pm$ 0.10 & 3.72 $\pm$ 0.07 & 3.73 $\pm$ 0.09 & 3.72 $\pm$ 0.09 & NS & $<$0.0001 & NS \\
\hline
\end{tabular}}
\end{table}
|
PMC1283151_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Type of post consultation letter} & \textbf{Letter to General Practitioner} & \textbf{Letter to patient} & \textbf{Significance (Wilcoxin Signed Ranks test)} \\
\hline
Length of time to dictate letter (minutes $\pm$ SD, n) & 3.28 $\pm$ 2.2, 81 & 2.57 $\pm$ 1.42, 82 & p = 0.019 \\
\hline
Flesch Reading Ease Score & 49.76 $\pm$ 9.1, 84 & 55.44 $\pm$ 9.26, 84 & p $<$ 0.001 \\
\hline
Flesch-Kincaid Grade Level & 10.72 $\pm$ 1.43 & 11.04 $\pm$ 1.39 & p = 0.062 \\
\hline
Circled items in each letter & 31/63 circled 1–12 items & 16/63 circled 1–5 items & p $<$ 0.001 \\
\hline
Word Count & 444 $\pm$ 169.87 & 351.5 $\pm$ 129.05 & p $<$ 0.001 \\
\hline
\end{tabular}}
\end{table}
|
PMC1360088_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{dvSalt30}} & \multicolumn{2}{|l|}{\textbf{ecox}} & \multicolumn{2}{|l|}{\textbf{shHeat5}} & \multicolumn{2}{|l|}{\textbf{shCold5}} \\
\hline
\textbf{Method} & \textbf{#Genes} & \textbf{\%Agree} & \textbf{#Genes} & \textbf{\%Agree} & \textbf{#Genes} & \textbf{\%Agree} & \textbf{#Genes} & \textbf{\%Agree} \\
\hline
1-gene (OpWise) & 220 & 100\% & 1062 & 98\% & 1002 & 97\% & 187 & 100\% \\
\hline
operon-wise & 401 & 99\% & 1318 & 100\% & 1284 & 99\% & 374 & 100\% \\
\hline
no-bias & 1090 & 90\% & 1269 & 98\% & 3020 & 87\% & 3063 & 70\% \\
\hline
SAM & 852 & 94\% & 957 & 99\% & 3348 & 83\% & 3258 & 68\% \\
\hline
\end{tabular}}
\end{table}
|
PMC1397872_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{AAA model} & \textbf{P (mmHg)} & \textbf{dAAA,max (cm)} & \textbf{Thickness t (cm)} & \textbf{$\alpha$} & \textbf{$\beta$} & \textbf{Stress (Authors' results) (MPa)} & \multicolumn{2}{|l|}{\textbf{Modified Laplace Equation}} & \multicolumn{2}{|l|}{\textbf{Original Laplace Equation}} \\
\hline
& & & & & & & \textbf{Stress (MPa)} & \textbf{Error} & \textbf{Stress (MPa)} & \textbf{Error} \\
\hline
Fillinger [3,4] & 120 & 6.7 & 0.19 & 0 & 0.4 & 0.32 & 0.34 & 6.3\% & 0.28 & 13\% \\
\hline
& 130 & 5.5 & 0.19 & 0 & 0.4 & 0.30 & 0.28 & 6.7\% & 0.25 & 16.7\% \\
\hline
Wang [29] & 128 & 6.1 & 0.184 & 0.54 & 0.33 & 0.19 & 0.208 & 9.5\% & 0.28 & 47\% \\
\hline
& 155 & 6.4 & 0.175 & 0.29 & 0.9 & 0.35 & 0.34 & 2.9\% & 0.38 & 8.6\% \\
\hline
Vorp [36] & 120 & 6.0 & 0.15 & 0 & 0.3 & 0.33 & 0.34 & 3\% & 0.31 & 6\% \\
\hline
Raghavan [45] & 115 & 5.2 & 0.19 & 0 & 0.65 & 0.23 & 0.21 & 8.7\% & 0.2 & 13\% \\
\hline
& 188 & 5.5 & 0.19 & 0 & 0.9 & 0.43 & 0.46 & 6.9\% & 0.36 & 16\% \\
\hline
Thubrikar [15] & 120 & 5.86 & 0.104 & 0 & 0.5 & 0.37 & 0.39 & 5.4\% & 0.45 & 22\% \\
\hline
& 120 & 5.86 & 0.158 & 0 & 0.5 & 0.3 & 0.299 & 0.3\% & 0.29 & 3.3\% \\
\hline
Li [44] & 120 & 5.0 & 0.05 & 0.15 & 1 & 0.43 & 0.41 & 4.6\% & 0.80 & 85.6\% \\
\hline
\end{tabular}}
\end{table}
|
PMC1421417_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Effect Size} & \textbf{Failure Rate 95\%} & \textbf{Failure Rate 98\%} \\
\hline
30\% & 235 & 195 \\
\hline
33.3\% & 185 & 160 \\
\hline
35\% & 160 & 140 \\
\hline
40\% & 120 & 95 \\
\hline
\end{tabular}}
\end{table}
|
PMC1459124_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Source} & \textbf{DF} & \multicolumn{5}{|l|}{\textbf{F value}} \\
\hline
& & \textbf{Critical} & \textbf{Dorsal vein} & \textbf{Caudal vein} & \textbf{Dorsal artery} & \textbf{Caudal artery} \\
\hline
Family & 3 & 2.91 & 11.35* & 1.35 & 8.74* & 0.58 \\
\hline
Environment & 1 & 4.16 & 1.87 & 3.70 & 12.10* & 7.71* \\
\hline
Family $\times$ Environment & 3 & 2.91 & 0.30 & 0.30 & 2.11 & 0.46 \\
\hline
Error & 38 \\
\hline
\end{tabular}}
\end{table}
|
PMC1479343_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{(µg/ml) Compound} & \textbf{IL-8 released (pg/ml)} \\
\hline
Medium alone & 24.6 $\pm$ 1.5 \\
\hline
Tryptase 2.0 & 105.2 $\pm$ 5.3* \\
\hline
Elastase 0.3 & 108.4 $\pm$ 13.2* \\
\hline
Benzamidine 30 & 37.6 $\pm$ 4.4 \\
\hline
Leupeptine 30 & 27.4 $\pm$ 5.6 \\
\hline
MSACK 30 & 22.1 $\pm$ 4.3 \\
\hline
Tryptase 2.0 + Benzamidine 30 & 66.9 $\pm$ 4.8† \\
\hline
Tryptase 2.0 + Leupeptin 30 & 100 $\pm$ 1.7 \\
\hline
Elastase 0.3 + MSACK 30 & 26.9 $\pm$ 3.6† \\
\hline
\end{tabular}}
\end{table}
|
PMC1489934_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{2}{|l|}{\textbf{Unemployment Duration (\%/n)}} & \textbf{t (p)} \\
\hline
& \textbf{Short-term N = 234} & \textbf{Long-term N = 195} \\
\hline
\multicolumn{4}{|l|}{Depression (in past 12 months)} \\
\hline
Never & 15.8/37 & 16.4/32 & 0.17 (sn) \\
\hline
Sometimes & 50.4/118 & 32.8/64 & 3.75 (p $<$ 0.001) \\
\hline
Often & 29.5/69 & 39.5/77 & 2.17 (p $<$ 0.05) \\
\hline
Always & 4.3/10 & 11.3/22 & 2.67 (p $<$ 0.01) \\
\hline
\multicolumn{4}{|l|}{Depression (after unemployment)} \\
\hline
Do not feel at all & 14.1/33 & 11.8/23 & 0.71 (sn) \\
\hline
No significant changes & 43.2/101 & 33.8/66 & 2.01 (p $<$ 0.05) \\
\hline
Feel more often & 39.7/93 & 51.8/101 & 2.52 (p $<$ 0.05) \\
\hline
Feel less & 3.0/7 & 2.6/5 & 0.25 (sn) \\
\hline
\multicolumn{4}{|l|}{Use of sedative drugs} \\
\hline
At least once in the last 30 days & 19.2/45 & 25.6/50 & 1.58 (sn) \\
\hline
\end{tabular}}
\end{table}
|
PMC1526724_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Year} & \textbf{Estimated population#} & \textbf{Birth cohort} & \textbf{Vaccination coverage*} & \textbf{Vaccine efficacy**} & \textbf{Children susceptible} & \textbf{Cumulated susceptible population} \\
\hline
1988 & 2,076,264 & 44,432 & 103.19\% & 85\% & 5,459 & 5,459 \\
\hline
1989 & 2,091,648 & 46,853 & 105.50\% & 85\% & 4,837 & 10,296 \\
\hline
1990 & 2,107,146 & 44,461 & 101.67\% & 85\% & 6,038 & 16,334 \\
\hline
1991 & 2,122,759 & 44,153 & 100.65\% & 85\% & 6,378 & 22,712 \\
\hline
1992 & 2,138,488 & 44,267 & 104.57\% & 85\% & 4,921 & 27,633 \\
\hline
1993 & 2,154,333 & 42,009 & 102.70\% & 85\% & 5,337 & 32,970 \\
\hline
1994 & 2,170,295 & 41,670 & 102.51\% & 85\% & 5,362 & 38,332 \\
\hline
1995 & 2,186,376 & 44,383 & 104.92\% & 85\% & 4,803 & 43,135 \\
\hline
1996 & 2,202,576 & 42,289 & 101.57\% & 85\% & 5,779 & 48,913 \\
\hline
1997 & 2,218,896 & 42,603 & 100.74\% & 85\% & 6,124 & 55,037 \\
\hline
1998 & 2,235,337 & 42,918 & 99.28\% & 85\% & 6,700 & 61,737 \\
\hline
1999 & 2,251,900 & 43,462 & 101.25\% & 85\% & 6,058 & 67,795 \\
\hline
2000 & 2,268,586 & 43,784 & 101.13\% & 85\% & 6,148 & 73,944 \\
\hline
2001 & 2,285,395 & 44,108 & 105.18\% & 85\% & 4,674 & 78,617 \\
\hline
2002 & 2,302,329 & 44,435 & 102.56\% & 85\% & 5,697 & 84,314 \\
\hline
2003 & 2,319,388 & 44,764 & 101.46\% & 85\% & 6,159 & 90,473 \\
\hline
2004 & 2,336,574 & 45,096 & 99.57\% & 85\% & 6,928 & 97,401 \\
\hline
\end{tabular}}
\end{table}
|
PMC1586205_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
Class & \multicolumn{14}{|l|}{3 1065 [336]} \\
\hline
Subclass & 3.1 267 [113] & \multicolumn{2}{|l|}{3.2 163 [56]} & 3.3 10 [4] & 3.4 317 [49] & 3.5 171 [70] & 3.6 109 [36] & 3.7 10 [4] & 3.8 10 [1] & 3.9 1 [1] & 3.10 2 [1] & 3.11 2 [0] & 3.12 1 [1] & 3.13 2 [0] \\
\hline
Sub- subclass & & 3.2.1 140 [45] & 3.2.2 23 [11] \\
\hline
\end{tabular}}
\end{table}
|
PMC1609188_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Authors} & \textbf{No. of Subjects} & \textbf{Test} & \textbf{Sensitivity (\%)} & \textbf{Specificity (\%)} & \textbf{QUADAS Score} \\
\hline
Thomas et al [24] & 297 & Kernig & 5* & 95* \\
\hline
& & & 9** & 96** & 7 \\
\hline
& & & 0*** & 95*** \\
\hline
& & Brudzinski & 5* & 95* \\
\hline
& & & 9** & 96** \\
\hline
& & & 25** & 96** \\
\hline
\end{tabular}}
\end{table}
|
PMC1635718_table_7
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Village} & \textbf{Paddy category} & \textbf{No. of Habitats} & \textbf{1stinstars} & \textbf{2nd instars} & \textbf{3rd instars} & \textbf{4th instars} & \textbf{Pupae} \\
\hline
Kangichiri & Ploughed & 25 & 1.41 & 0.95 & 0.09 & 0.00 & 0.36 \\
\hline
& Flooded & 23 & 1.67 & 1.10 & 0.30 & 0.00 & 0.36 \\
\hline
& Post transplanting & 30 & 6.02 & 3.00 & 1.89 & 1.20 & 0.99 \\
\hline
& Tillering & 28 & 8.00 & 6.67 & 2.00 & 3.22 & 0.67 \\
\hline
& Flowering/ maturation & 27 & 0.01 & 0.00 & 0.02 & 0.01 & 0.00 \\
\hline
& Fallow & 27 & 1.00 & 0.67 & 0.00 & 0.00 & 0.01 \\
\hline
Kiuria & Ploughed & 22 & 0.00 & 0.00 & 0.00 & 0.00 & 0.00 \\
\hline
& Flooded & 23 & 1.23 & 0.65 & 0.07 & 0.01 & 0.0 \\
\hline
& Post transplanting & 21 & 5.58 & 1.63 & 0.17 & 0.51 & 0.19 \\
\hline
& Tillering & 22 & 8.50 & 5.25 & 0.25 & 0.25 & 1.25 \\
\hline
& Flowering/ maturation & 20 & 0.02 & 0.00 & 0.01 & 0.0 & 0.00 \\
\hline
& Fallow & 14 & 0.03 & 0.01 & 0.0 & 0.01 & 0.00 \\
\hline
Rurumi & Ploughed & 18 & 0.00 & 0.00 & 0.00 & 0.00 & 0.00 \\
\hline
& Flooded & 21 & 1.56 & 1.28 & 0.09 & 0.06 & 0.19 \\
\hline
& Post transplanting & 20 & 5.73 & 3.37 & 1.17 & 1.03 & 0.47 \\
\hline
& Tillering & 20 & 4.91 & 4.67 & 1.19 & 1.11 & 1.00 \\
\hline
& Flowering/ maturation & 15 & 0.00 & 0.00 & 0.00 & 0.00 & 0.00 \\
\hline
& Fallow & 12 & 1.17 & 0.00 & 0.00 & 0.00 & 0.00 \\
\hline
\end{tabular}}
\end{table}
|
PMC1636646_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Respondents}} & \multicolumn{2}{|l|}{\textbf{Dropouts}} \\
\hline
\textbf{Characteristics at baseline} & \textbf{N} & \textbf{\%} & \textbf{N} & \textbf{\%} \\
\hline
\multicolumn{5}{|l|}{Age (years)} \\
\hline
$<$ 30 & 273 & 6.7 & 137 & 13.7 \\
\hline
30–39 & 824 & 20.2 & 221 & 22.1 \\
\hline
40–49 & 1778 & 43.6 & 338 & 33.8 \\
\hline
50–59 & 1065 & 26.1 & 265 & 26.5 \\
\hline
$>$ 59 & 136 & 3.3 & 39 & 3.9 \\
\hline
\multicolumn{5}{|l|}{Gender} \\
\hline
Female & 3912 & 96.0 & 947 & 94.9 \\
\hline
Male & 164 & 4.0 & 51 & 5.1 \\
\hline
\multicolumn{5}{|l|}{Marital status} \\
\hline
Married or cohabiting & 3271 & 80.3 & 771 & 77.3 \\
\hline
Single & 800 & 19.7 & 227 & 22.7 \\
\hline
\multicolumn{5}{|l|}{Have preschool children} \\
\hline
No & 3490 & 87.0 & 843 & 85.8 \\
\hline
Yes & 522 & 13.0 & 140 & 14.2 \\
\hline
\multicolumn{5}{|l|}{Special tasks of care taking during leisure time †} \\
\hline
No & 2944 & 72.6 & 721 & 72.6 \\
\hline
Yes & 1112 & 27.4 & 272 & 27.4 \\
\hline
\multicolumn{5}{|l|}{Pregnant} \\
\hline
No & 3978 & 99.1 & 955 & 98.0 \\
\hline
Yes & 37 & 0.9 & 19 & 2.0 \\
\hline
\multicolumn{5}{|l|}{Long-term health problems (any kind)} \\
\hline
No or "yes, but not bothered" & 3006 & 74.4 & 736 & 74.4 \\
\hline
Yes, and bothered by it & 1033 & 25.6 & 253 & 25.6 \\
\hline
\multicolumn{5}{|l|}{Regular physical exercise} \\
\hline
No & 1724 & 42.4 & 451 & 45.2 \\
\hline
Yes & 2343 & 57.6 & 547 & 54.8 \\
\hline
\multicolumn{5}{|l|}{Years of experience as nurses' aide} \\
\hline
$<$ 10 years & 706 & 17.3 & 235 & 23.5 \\
\hline
10 years or more & 3370 & 82.7 & 764 & 76.5 \\
\hline
\end{tabular}}
\end{table}
|
PMC1693921_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{CDS} & \textbf{Gene name} & \textbf{Predicted function} & \textbf{m-value RES167} & \textbf{m-value CL1} \\
\hline
\multicolumn{5}{|l|}{BIOTIN BIOSYNTHESIS AND TRANSPORT} \\
\hline
cg0095 & bioB & biotin synthase & 3.69 & 1.55 \\
\hline
cg2147 & bioY & membrane protein, BioY family & 3.70 & 1.51 \\
\hline
cg2148 & & ABC transporter, ATP-binding protein & 3.11 & 1.51 \\
\hline
cg2149 & & permease (cobalt permease subfamily) & 1.63 & 0.75* \\
\hline
cg2885 & bioA & adenosylmethionine-8-amino-7-oxononanoate aminotransferase & 2.09 & 0.91* \\
\hline
cg2886 & bioD & dethiobiotin synthetase protein & 1.32 & 0.76* \\
\hline
cg1227 & & ABC-type cobalt transport system & 1.58 & 1.48 \\
\hline
\multicolumn{5}{|l|}{FUNCTION UNKNOWN} \\
\hline
cg0378 & & putative phage-associated protein & 1.14 & 1.61 \\
\hline
\multicolumn{5}{|l|}{SULFONATE (ESTER) METABOLISM AND TRANSPORT} \\
\hline
cg1147 & ssuI & reductase involved in sulfonate degradation & -1.25 & -1.70 \\
\hline
cg1152 & seuB & sulfonate ester monoxygenase & -1.35 & -1.25 \\
\hline
cg1153 & seuC & sulfonate ester monooxygenase & -0.99* & -1.07 \\
\hline
cg1156 & ssuD2 & alkanesulfonate monooxygenase & -2.23 & -1.00 \\
\hline
cg1376 & ssuD1 & alkanesulfonate monooxygenase & -2.11 & -1.61 \\
\hline
cg1377 & ssuC & aliphatic sulfonates ABC transporter & -2.17 & -1.32 \\
\hline
cg1379 & ssuB & aliphatic sulfonates ABC transporter & -1.75 & -0.74* \\
\hline
\multicolumn{5}{|l|}{CELL DIVISION} \\
\hline
cg2378 & mraZ & MraZ protein & -1.02 & -1.16 \\
\hline
\end{tabular}}
\end{table}
|
PMC1779776_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Accession no} & \textbf{Symbol} & \textbf{Gene Name} & \textbf{Reference} \\
\hline
\multicolumn{4}{|l|}{Chemokines and receptors} \\
\hline
[genebank:NM_002983] & CCL3 & $\pi$ Chemokine, CC motif, Ligand 3 & [25] \\
\hline
[genebank:NM_002984] & CCL4 & $\pi$ Chemokine, CC motif, ligand 4 & [25] \\
\hline
[genebank:NM_005408] & CCL13 & Chemokine, CC motif, ligand 13 & [68] \\
\hline
[genebank:NM_032964] & CCL15 & Chemokine, CC motif, ligand 15 & [69] \\
\hline
[genebank:NM_006274] & CCL19 & Chemokine, CC motif, ligand 19 & -1748* \\
\hline
[genebank:NM_002990] & CCL22 & $\pi$ Chemokine, CC motif, ligand 22 & [70] \\
\hline
[genebank:NM_001511] & CXCL1 & $\pi$ Chemokine CC motif, Ligand 1 & [25] \\
\hline
[genebank:NM_002089] & CXCL2 & $\pi$ Chemokine, CXC motif, ligand 2 & [25] \\
\hline
[genebank:NM_000584] & CXCL8 & $\pi$ Chemokine, CXC motif, ligand 8 & [25] \\
\hline
[genebank:NM_001565] & CXCL10 & Chemokine, CXC motif, ligand 10 & [25] \\
\hline
[genebank:NM_005408] & CXCL13 & Chemokine, CXC motif, ligand 13 & -1593* \\
\hline
[genebank:U28934] & CCR2 & Chemokine, CC motif, receptor 2 & -1543* \\
\hline
[genebank:NM_003467] & CXCR4 & $\pi$ Chemokine, CXC motif, receptor 4 & [71] \\
\hline
\multicolumn{4}{|l|}{Cytokines and Receptors} \\
\hline
[genebank:NM_000594] & TNF-$\alpha$ & $\alpha$ $\pi$ Tumour Necrosis Factor & [25] \\
\hline
[genebank:NM_000576] & IL1-$\beta$ & Interleukin 1 B $\pi$ & [25] \\
\hline
[genebank:NM_000577] & IL1-RN & $\pi$ Interleukin 1 receptor antagonist & [25] \\
\hline
[genebank:NM_005746] & PBEF & $\pi$ Pre B cell colony stimulating factor 1 & -533*, -479* \\
\hline
[genebank:NM_001250] & TNFRSF5 & TNF receptor superfamily, member 5 & [72] \\
\hline
[genebank:NM_001561] & TNFRSF9 & TNF receptor superfamily member 9 & [73] \\
\hline
[genebank:NM_005534] & IFNGR2 & Interferon, gamma receptor 2 & -317, -220*, -144, -134* \\
\hline
\multicolumn{4}{|l|}{Stress} \\
\hline
[genebank:NM_000636] & SOD2 & $\pi$p Superoxide dismutase 2 & [25] \\
\hline
[genebank:NM_000963] & COX2 & Cycloxygenase 2 $\pi$ & [25] \\
\hline
[genebank:NM_006427] & TXNIP & $\pi$ Thioredoxin interacting protein & -618 \\
\hline
\multicolumn{4}{|l|}{Apoptosis} \\
\hline
[genebank:NM_015675] & $\beta$ GADD45 & $\pi$ Growth arrest and DNA damage inducible gene GADD45, B & [74] \\
\hline
[genebank:NM_005879] & TRIP & Traf interacting protein & -1736 \\
\hline
[genebank:NM_006290] & TNFAIP3 & $\alpha$ $\pi$ Tumour Necrosis factor induced protein 3 & [25] \\
\hline
[genebank:NM_001165] & cIAP2 & $\pi$ Cellular inhibitor of apoptosis 2 & [75] \\
\hline
\multicolumn{4}{|l|}{Transcription} \\
\hline
[genebank:NM_020529] & I$\kappa$B-$\alpha$ & Inhibitor of $\kappa$light chain gene enhancer in B cells; $\alpha$ $\pi$ & [25] \\
\hline
[genebank:NM_003998] & NF$\kappa$B1 & $\kappa$B, $\pi$ Nuclear factor of subunit 1 & [25] \\
\hline
[genebank:NM_002908] & C-REL & $\pi$ V-rel avain reticuloendotheliosis viral oncogene homolog; rel & [25] \\
\hline
[genebank:NM_005375] & C-MYB & $\pi$ V-MYB avian myeloblastosis viral oncogene homolog & [25] \\
\hline
[genebank:NM_004364] & CEBP$\alpha$ & $\alpha$ CAAT/enhancer binding protein & [25] \\
\hline
[genebank:U96131] & TRIP13 & Thyroid hormone interactor 13 & -1611, -1601*, -1600* -1464* \\
\hline
[genebank:NM_002129] & HMGB2 & High mobility group box 2 & -1531, -1520, -1087 \\
\hline
\multicolumn{4}{|l|}{Cell Cycle/Differentiation} \\
\hline
[genebank:NM_006763] & BTG2 & $\pi$ B-cell translocation gene 2 & [76] \\
\hline
[genebank:NM_002166] & ID2 & $\pi$ Inhibitor of DNA binding 2 & -571*, -174 \\
\hline
[genebank:X54941] & CKS1B & CDC28 protein kinase 1B & -1416, -1406* -717, -647, -637*, -646 -636* \\
\hline
[genebank:NM_004701] & CCNB2 & Cyclin B2 & -1387 \\
\hline
\multicolumn{4}{|l|}{Growth} \\
\hline
[genebank:NM_000598] & IGFBP3 & $\pi$ Insulin-like growth-factor binding protein 3 & -1729 \\
\hline
\multicolumn{4}{|l|}{Miscellaneous} \\
\hline
[genebank:NM_000674] & ADORA1 & Adenosine A1 receptor & [25] \\
\hline
[genebank:NM_000201] & ICAM1 & $\pi$ Intracellular adhesion molecule 1 & [25] \\
\hline
[genebank:NM_002421] & MMP1 & Matrix metalloproteinase 1 & [25] \\
\hline
[genebank:X13895] & SAA3P & Serum amyloid A3 pseudogene & -1790* \\
\hline
[genebank:NM_002291] & LAM$\beta$1 & $\beta$ Laminin, 1 & -263, -253 \\
\hline
[genebank:NM_004119] & FLT3 & FMS related tyrosine kinase 3 & -295, -285* \\
\hline
[genebank:NM_001365] & DLG4 & Discs, large homolog 4 & -1425, -1415*, -544* \\
\hline
[genebank:M22001] & F13A1 & Coagulation factor X111, A1 polypeptide & -404, -72* \\
\hline
\end{tabular}}
\end{table}
|
PMC1781469_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Scoliosis} & \textbf{Karyotype} \\
\hline
12° Right thoracic, hypokyphosis & 45XO \\
\hline
30° Right Thoraco-lumbar & 45XO \\
\hline
18° Right thoracic, hypokyphosis & 46XisoX(q10) Mosaic \\
\hline
30° Right Thoraco-lumbar & 45XO \\
\hline
No Xrays Mild clinical deformity Right thoracic & 45XO \\
\hline
17° Left Thoraco-lumbar & 45XO \\
\hline
18° Right thoracic, hypokyphosis & 45XO \\
\hline
55° Right thoracic Scoliosis surgery & 45XO \\
\hline
45° Right thoracic, hypokyphosis & 45XO \\
\hline
10° Right lumbar & Diagnosed South Africa. Karyotype not available. \\
\hline
20° Left Thoraco-lumbar & 45XO \\
\hline
12° left Thoraco-lumbar & 45XO/46XY mosaic Undiagnosed syndrome \\
\hline
45° Right Thoracic, hypokyphosis & 45XO \\
\hline
\end{tabular}}
\end{table}
|
PMC1808441_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{$\delta$} & \textbf{C1} & \textbf{C2} & \textbf{C3} & \textbf{C4} & \textbf{C5} & \textbf{C6} & \textbf{C7} & \textbf{C8} & \textbf{C9} & \textbf{C} & \textbf{V} & \textbf{V1} & \textbf{V2} & \textbf{V3} & \textbf{V4} & \textbf{V5} & \textbf{V6} & \textbf{V7} & \textbf{V8} \\
\hline
C1 & 0 & 4.40 & 5.08 & 4.63 & 4.65 & 5.08 & 4.26 & 4.70 & 3.52 & 2.55 & 3.70 & 3.62 & 2.80 & 3.67 & 3.77 & 3.37 & 3.70 & 4.00 & 3.25 \\
\hline
C2 & & 0 & 6.25 & 5.77 & 5.93 & 6.38 & 5.90 & 4.65 & 5.37 & 2.58 & 4.60 & 4.46 & 3.47 & 4.53 & 4.72 & 4.96 & 4.94 & 4.72 & 3.78 \\
\hline
C3 & & & 0 & 6.00 & 6.62 & 5.69 & 5.77 & 5.35 & 5.35 & 2.85 & 4.86 & 4.78 & 4.07 & 4.51 & 4.71 & 4.87 & 5.18 & 4.76 & 4.73 \\
\hline
C4 & & & & 0 & 6.36 & 5.71 & 5.22 & 5.06 & 5.09 & 2.65 & 4.95 & 4.70 & 3.48 & 4.85 & 5.14 & 5.04 & 4.13 & 5.26 & 4.28 \\
\hline
C5 & & & & & 0 & 6.86 & 6.08 & 6.17 & 5.00 & 2.97 & 4.88 & 4.81 & 3.64 & 4.96 & 5.35 & 4.95 & 5.41 & 4.71 & 4.54 \\
\hline
C6 & & & & & & 0 & 6.21 & 4.70 & 5.25 & 3.18 & 4.70 & 4.60 & 3.40 & 4.75 & 4.74 & 4.75 & 4.67 & 5.20 & 3.90 \\
\hline
C7 & & & & & & & 0 & 4.92 & 4.85 & 2.37 & 4.71 & 5.15 & 3.93 & 5.16 & 4.99 & 4.93 & 4.63 & 4.47 & 4.88 \\
\hline
C8 & & & & & & & & 0 & 4.34 & 2.66 & 4.68 & 3.77 & 3.20 & 4.25 & 4.11 & 4.80 & 4.04 & 4.50 & 3.36 \\
\hline
C9 & & & & & & & & & 0 & 2.48 & 3.84 & 3.92 & 3.22 & 4.16 & 4.32 & 4.13 & 4.84 & 4.00 & 3.32 \\
\hline
C & & & & & & & & & & 0 & 3.35 & 3.64 & 3.19 & 3.70 & 3.78 & 3.62 & 3.99 & 2.96 & 3.01 \\
\hline
V & & & & & & & & & & & 0 & 2.25 & 2.07 & 1.91 & 2.11 & 2.09 & 2.21 & 1.87 & 2.36 \\
\hline
V1 & & & & & & & & & & & & 0 & 2.41 & 3.79 & 3.26 & 3.07 & 3.59 & 3.64 & 3.57 \\
\hline
V2 & & & & & & & & & & & & & 0 & 2.79 & 2.73 & 2.71 & 2.59 & 2.77 & 2.34 \\
\hline
V3 & & & & & & & & & & & & & & 0 & 3.63 & 3.77 & 3.60 & 4.54 & 3.41 \\
\hline
V4 & & & & & & & & & & & & & & & 0 & 3.57 & 3.66 & 4.09 & 4.03 \\
\hline
V5 & & & & & & & & & & & & & & & & 0 & 4.08 & 3.77 & 3.69 \\
\hline
V6 & & & & & & & & & & & & & & & & & 0 & 4.25 & 3.52 \\
\hline
V7 & & & & & & & & & & & & & & & & & & 0 & 3.83 \\
\hline
V8 & & & & & & & & & & & & & & & & & & & 0 \\
\hline
\end{tabular}}
\end{table}
|
PMC1847453_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Patient characteristics} & \multicolumn{3}{|l|}{\textbf{Group}} & \textbf{P-value} \\
\hline
& \textbf{Faculty physician (\%)} & \textbf{General doctor (\%)} & \textbf{Resident (\%)} \\
\hline
Mean age (SD), years & 50.39 (15.65) & 49.32 (15.86) & 49.55 (15.39) & 0.07 \\
\hline
\multicolumn{5}{|l|}{Sex} \\
\hline
Male & 233 (30.50) & 92 (24.90) & 249 (31.50) & 0.07 \\
\hline
Female & 530 (69.50) & 277 (75.10) & 542 (68.50) \\
\hline
\multicolumn{5}{|l|}{Status of patients} \\
\hline
New patients & 113 (14.50) & 75 (16.40) & 235 (36.70) & 0.00 \\
\hline
Existing patients & 665 (85.50) & 382 (83.60) & 405 (63.30) \\
\hline
\multicolumn{5}{|l|}{Funding of patient} \\
\hline
Universal coverage & 37 (4.70) & 8 (1.80) & 30 (4.70) & 0.10 \\
\hline
Social welfare & 62 (7.90) & 38 (8.40) & 38 (5.90) \\
\hline
Government welfare & 416 (53.10) & 248 (54.70) & 294 (45.80) \\
\hline
Self-payment & 269 (34.30) & 159 (35.10) & 280 (43.60) \\
\hline
\multicolumn{5}{|l|}{Chronic illness} \\
\hline
yes & 259 (35.60) & 141 (33.30) & 199 (34.40) & 0.68 \\
\hline
no & 469 (64.40) & 286 (66.70) & 379 (65.60) \\
\hline
\multicolumn{5}{|l|}{Accommodation} \\
\hline
Owner & 566 (72.80) & 322 (72.20) & 436 (69.40) & 0.36 \\
\hline
Renting & 212 (27.20) & 124 (27.80) & 192 (30.60) \\
\hline
\multicolumn{5}{|l|}{Occupation} \\
\hline
Business owner & 51 (7.10) & 33 (7.90) & 40 (7.0) & 0.47 \\
\hline
Employee & 155 (21.70) & 98 (23.30) & 154 (27.00) \\
\hline
Government worker & 121 (16.90) & 81 (19.30) & 95 (16.60) \\
\hline
Student & 39 (5.50) & 20 (4.80) & 33 (5.80) \\
\hline
Housewife & 234 (32.80) & 134 (31.90) & 167 (29.20) \\
\hline
Unemployed & 5 (0.70) & 1 (0.20) & 7 (1.20) \\
\hline
Disabled & 14 (2.00) & 10 (2.40) & 15 (2.60) \\
\hline
Retired & 95 (13.30) & 43 (10.20) & 60 (10.50) \\
\hline
\multicolumn{5}{|l|}{Income (Baht/month)} \\
\hline
$<$ 5,000 & 50 (14.20) & 68 (21.20) & 33 (15.20) & 0.13 \\
\hline
5,001–10,000 & 113 (32.10) & 106 (33.00) & 66 (30.40) \\
\hline
10,001–30,000 & 160 (45.50) & 131 (40.80) & 108 (49.80) \\
\hline
30,001–50,000 & 21 (6.00) & 11 (3.40) & 6 (2.80) \\
\hline
$>$50,000 & 8 (2.30) & 5 (1.60) & 4 (1.80) \\
\hline
\end{tabular}}
\end{table}
|
PMC1852109_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Variables} & \textbf{N (\%)} & \textbf{Mean} & \textbf{Std. Deviation} & \textbf{Min} & \textbf{Max} \\
\hline
Gender & 12376 & - & - & - & - \\
\hline
Males & 5660 (45.3) & - & - & - & - \\
\hline
Females & 6716 (54.3) & - & - & - & - \\
\hline
Body Mass Index & 10961§ & 25.75 & 4.84 & 9.60 & 57.80 \\
\hline
Under/Normal weight & 5449 (49.7) & - & - & - & - \\
\hline
Overweight & 3710 (33.8) & - & - & - & - \\
\hline
Obese & 1802 (16.4) & - & - & - & - \\
\hline
Depression (# years with MDE-lifetime) & 12282§ & 0.41 & 8.20 & 0 & 67.00 \\
\hline
No depression (0 years) & 10826 (88.1) & - & - & - & - \\
\hline
Yes depression & 1456 (11.9) & - & - & - & - \\
\hline
Physical Activity & 12375§ & 2.27 & 2.34 & 0 & 28.70 \\
\hline
Stress Management & 12352§ & 2.31 & 0.93 & 1 & 5 \\
\hline
Eating Habits & 1812§ & 10.63 & 8.85 & 0 & 62 \\
\hline
Relatives with Depression & 1512§ & 1.76 & 3.02 & 0 & 55 \\
\hline
\end{tabular}}
\end{table}
|
PMC1868752_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Ages (years)} & \textbf{\% Seronegative} & \textbf{Risk among seronegative women/100 pregnancies*} & \textbf{Risk for all women/100 pregnancies} & \textbf{No. live-birth pregnancies (100's)†} & \textbf{No. women with primary infection during live-birth pregnancies} \\
\hline
\multicolumn{6}{|l|}{Non-Hispanic White} \\
\hline
12–19 & 61.0 & 0.15 & 0.09 & 2320 & 209 \\
\hline
20–29 & 56.7 & 1.38 & 0.78 & 12140 & 9469 \\
\hline
30–39 & 49.4 & 1.38 & 0.68 & 9120 & 6201 \\
\hline
40–49 & 38.9 & 1.38 & 0.54 & 510 & 275 \\
\hline
Subtotal & & & & 24090 & 16154 \\
\hline
\multicolumn{6}{|l|}{Non-Hispanic Black} \\
\hline
12–19 & 42.6 & 7.33 & 3.12 & 1330 & 4150 \\
\hline
20–29 & 17.8 & 3.40 & 0.61 & 3060 & 1867 \\
\hline
30–39 & 13.4 & 3.40 & 0.46 & 1350 & 621 \\
\hline
40–49 & 5.3 & 3.40 & 0.18 & 80 & 14 \\
\hline
Subtotal & & & & 5820 & 6652 \\
\hline
\multicolumn{6}{|l|}{Mexican American} \\
\hline
12–19 & 30.1 & 2.21 & 0.67 & 1220 & 817 \\
\hline
20–29 & 17.5 & 3.85 & 0.67 & 3990 & 2673 \\
\hline
30–39 & 10.5 & 3.85 & 0.40 & 1700 & 680 \\
\hline
40–49 & 6.8 & 3.85 & 0.26 & 100 & 26 \\
\hline
Subtotal & & & & 7010 & 4196 \\
\hline
Total & & & & 36940 & 27002 \\
\hline
\end{tabular}}
\end{table}
|
PMC1925089_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Drug usea} & \multicolumn{2}{|l|}{\textbf{Invasion}} & \multicolumn{2}{|l|}{\textbf{Noninvasive}} & \multicolumn{2}{|l|}{\textbf{TP53 IHC Intensity}} \\
\hline
& \textbf{Noninvasive OR (95\%CI)b} & \textbf{Invasive OR (95\%CI)b} & \textbf{Low grade OR (95\%CI)b} & \textbf{High grade OR (95\%CI)b} & \textbf{$<$3 OR (95\%CI)b} & \textbf{3+ OR (95\%CI)b} \\
\hline
\\
\hline
Phenacetin & 2.4 (1.3–4.5) & 2.2 (0.9–5.1) & 2.2 (1.1–4.2) & 4.3 (1.0–17.9) & 2.0 (1.1–3.8) & 2.7 (1.2–6.5) \\
\hline
Paracetamol & 0.6 (0.3–1.1) & 1.1 (0.5–2.2) & 0.5 (0.2–0.9) & 2.0 (0.6–6.4) & 0.4 (0.2–0.8) & 1.7 (0.8–3.5) \\
\hline
All NSAIDs & 0.7 (0.4–1.0) & 0.5 (0.3–1.0) & 0.7 (0.5–1.1) & 0.4 (0.1–1.4) & 0.8 (0.5–1.2) & 0.5 (0.3–0.9) \\
\hline
Aspirin & 0.6 (0.3–1.0) & 0.4 (0.2–0.9) & 0.6 (0.4–1.0) & 0.5 (0.1–1.8) & 0.7 (0.4–1.1) & 0.4 (0.2–0.9) \\
\hline
Ibuprofen & 0.7 (0.4–1.3) & 0.7 (0.3–1.6) & 0.8 (0.4–1.4) & 0.3 (0.0–2.3) & 0.9 (0.5–1.6) & 0.6 (0.2–1.4) \\
\hline
\end{tabular}}
\end{table}
|
PMC2018698_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Diseases . . . .} & \textbf{Age} & \multicolumn{2}{|l|}{\textbf{a}} & \multicolumn{2}{|l|}{\textbf{b}} & \multicolumn{2}{|l|}{\textbf{c}} & \multicolumn{4}{|l|}{\textbf{MAPE (\%)}} \\
\hline
\textbf{. . . .} & & & & & & & & \multicolumn{2}{|l|}{\textbf{h = 2}} & \multicolumn{2}{|l|}{\textbf{h = 3}} \\
\hline
\textbf{. . . .} & & & & & & & & \textbf{MHW} & \textbf{SA3} & \textbf{MHW} & \textbf{SA3} \\
\hline
. . Diarrhea . . & 0–11 mo. & 0.01 & (0.03) & ,0.01 & (0.16) & 0.35 & (0.14) & 26.6 & 30.3 & 25.3 & 30.1 \\
\hline
. . . . & 1–4 yr. & 0.01 & (0.02) & ,0.01 & (0.04) & 0.32 & (0.16) & 23.2 & 30.3 & 22.8 & 30.2 \\
\hline
. . . . & 5–15 yr. & ,0.01 & (0.02) & 0.02 & (0.21) & 0.32 & (0.17) & 42.4 & 43.3 & 43.5 & 44.1 \\
\hline
. . . & .15 yr. & 0.11 & (0.19) & 0.03 & (0.15) & 0.23 & (0.17) & 26.2 & 32.9 & 27.0 & 33.8 \\
\hline
. . ARI . . & 0–11 mo. & 0.21 & (0.32) & ,0.01 & (,0.01) & 0.24 & (0.21) & 25.2 & 25.7 & 25.0 & 26.8 \\
\hline
. . . . & 1–4 yr. & 0.03 & (0.07) & ,0.01 & (0.02) & 0.31 & (0.19) & 22.5 & 28.2 & 22.9 & 30.0 \\
\hline
. . . . & 5–15 yr. & 0.07 & (0.09) & ,0.01 & (,0.01) & 0.30 & (0.15) & 25.9 & 25.3 & 26.3 & 26.7 \\
\hline
. . . & .15 yr. & 0.23 & (0.30) & ,0.01 & (,0.01) & 0.30 & (0.20) & 24.1 & 27.1 & 25.0 & 30.0 \\
\hline
. Malaria . . . & 0–11 mo. & 0.08 & (0.09) & ,0.01 & (,0.01) & 0.27 & (0.14) & 22.9 & 23.2 & 22.4 & 25.9 \\
\hline
. . . . & 1–4 yr. & 0.18 & (0.22) & ,0.01 & (0.22) & 0.24 & (0.13) & 23.1 & 28.4 & 22.9 & 30.5 \\
\hline
. . . & 5–15 yr. & 0.09 & (0.09) & ,0.01 & (0.06) & 0.30 & (0.16) & 22.7 & 20.9 & 22.4 & 23.2 \\
\hline
. . . & .15 yr. & 0.13 & (0.08) & 0.01 & (0.12) & 0.26 & (0.12) & 17.8 & 17.5 & 18.1 & 18.1 \\
\hline
\end{tabular}}
\end{table}
|
PMC2077810_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Sample size} & \multicolumn{3}{|l|}{\textbf{Power}} & \textbf{Type I error} \\
\hline
& \textbf{$\beta$3 = -0.65} & \textbf{$\beta$3 = -0.95} & \textbf{$\beta$3 = -1.20} & \textbf{$\beta$3 = 0} \\
\hline
150 & 0.348 & 0.642 & 0.780 & 0.052 \\
\hline
200 & 0.540 & 0.668 & 0.894 & 0.048 \\
\hline
250 & 0.604 & 0.852 & 0.898 & 0.054 \\
\hline
300 & 0.664 & 0.884 & 0.960 & 0.046 \\
\hline
400 & 0.760 & 0.948 & 1.000 & 0.050 \\
\hline
600 & 0.876 & 1.000 & 1.000 & 0.052 \\
\hline
\end{tabular}}
\end{table}
|
PMC2099440_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{VACCINE DOSE 1 . . . .} & \multicolumn{2}{|l|}{\textbf{Group 1, n = 12}} & \multicolumn{2}{|l|}{\textbf{Group 2, n = 13}} \\
\hline
\textbf{. . . .} & \textbf{n} & \textbf{\%} & \textbf{n} & \textbf{\%} \\
\hline
. Documented Fever .37.5 . . . & 1 & 8 & 0 & - \\
\hline
. Symptoms of feverish . . . & 2 & 17 & 4 & 31 \\
\hline
. Malaise . . . & 0 & - & 4 & 31 \\
\hline
Arthralgia . . . & 2 & 17 & 2 & 15 \\
\hline
. Headache . . . & 0 & - & 4 & 31 \\
\hline
. Myalgia . . . & 5 & 83 & 5 & 38 \\
\hline
. Nausea/vomiting . . & 0 & - & 0 & - \\
\hline
. VACCINE DOSE 2 . . . & \multicolumn{2}{|l|}{Group 1, n = 12} & \multicolumn{2}{|l|}{Group 2, n = 12} \\
\hline
. . . . & n & \% & n & \% \\
\hline
. .37.5 Document. Fever . . & 0 & - & 0 & - \\
\hline
. Symptoms of feverish . . . & 1 & 8 & 4 & 33 \\
\hline
. Malaise . . . & 1 & 8 & 5 & 42 \\
\hline
. Arthralgia . . & 1 & 8 & 1 & 8 \\
\hline
. . Headache . . & 0 & - & 3 & 25 \\
\hline
. Myalgia . . . & 3 & 25 & 6 & 50 \\
\hline
. Nausea/vomiting . . . & 0 & - & 1 & 8 \\
\hline
. VACCINE DOSE 3 . . & \multicolumn{2}{|l|}{Group 1, n = 12} & \multicolumn{2}{|l|}{Group 2, n = 12} \\
\hline
. . . . & n & \% & n & \% \\
\hline
. Documented Fever .37.5 . . . & 1 & 8 & 1 & 8 \\
\hline
. Symptoms of feverish . . & 1 & 8 & 4 & 33 \\
\hline
. . Malaise . . & 1 & 8 & 5 & 42 \\
\hline
. Arthralgia . . . & 1 & 8 & 3 & 25 \\
\hline
. Headache . . . & 0 & - & 3 & 25 \\
\hline
. Myalgia . . & 2 & 17 & 5 & 42 \\
\hline
. Nausea/vomiting . . & 0 & - & 1 & 8 \\
\hline
\end{tabular}}
\end{table}
|
PMC2204057_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Class} & \textbf{Subclass} & \textbf{Number of gene families} & \textbf{Number of genes} & \textbf{Number of pseudogenes} \\
\hline
ANTP & HOXL & 14 & 52 & 0 \\
\hline
& NKL & 23 & 48 & 19b \\
\hline
PRD & PAX & 3 & 7a & 0 \\
\hline
& PAXL & 28 & 43 & 24c, d \\
\hline
LIM & & 6 & 12 & 0 \\
\hline
POU & & 7 & 16 & 8e \\
\hline
HNF & & 2 & 3 & 0 \\
\hline
SINE & & 3 & 6 & 0 \\
\hline
TALE & & 6 & 20 & 10f \\
\hline
CUT & & 3 & 7 & 3g \\
\hline
PROS & & 1 & 2 & 0 \\
\hline
ZF & & 5 & 14 & 1h \\
\hline
CERS & & 1 & 5i & 0 \\
\hline
Totals & & 102 & 235a & 65b-h \\
\hline
\end{tabular}}
\end{table}
|
PMC2211742_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Group} & \multicolumn{4}{|l|}{\textbf{parasitaemia1 \% of (mg/ml)2 Concentration of IgG}} & \multicolumn{4}{|l|}{\textbf{inhibition4 \% of invasion Concentration of IgG (mg/ml)}} \\
\hline
\\
\hline
& \textbf{0.5} & \textbf{0.25} & \textbf{0.125} & \textbf{0.0625} & \textbf{0.5} & \textbf{0.25} & \textbf{0.125} & \textbf{0.0625} \\
\hline
Adjuvant control & (60.12)3 5.66 & 5.76 (61.25) & 6.13 (60.32) & 5.34 (60.58) & - & - & - \\
\hline
PfAARP immune & (60.31) 1.73 & (60.58) 2.63 & (60.7) 3 & (6013) 3.24 & 69.41 & 54.34 & 51.10 & 39.4 \\
\hline
MSP-142 immune & 2.07 (60.12) & 1.93 (60.12) & 2.86 (60.31) & 3.4 (60.01) & 63.50 & 66.50 & 53.30 & 36.3 \\
\hline
\end{tabular}}
\end{table}
|
PMC2253826_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Tilburg} & \textbf{Groningen} \\
\hline
Number of contacts between 00.00 and 08.00 h & 787 & 483 \\
\hline
Number of contacts between 08.00 and 24.00 h & 3466 & 2028 \\
\hline
\end{tabular}}
\end{table}
|
PMC2265289_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Estimators} & \multicolumn{2}{|l|}{\textbf{Lung cancer}} & \multicolumn{2}{|l|}{\textbf{Cervix cancer}} \\
\hline
& \textbf{Dispersion variance} & \textbf{Prediction variance} & \textbf{Dispersion variance} & \textbf{Prediction variance} \\
\hline
True risk values & 9.817 & - & 1.153 & - \\
\hline
Global Empirical Bayes & 6.059 & - & 0.537 & - \\
\hline
Local Empirical Bayes & 7.905 & - & 1.063 & - \\
\hline
BYM model & 7.034 & 2.791 & 0.757 & 0.347 \\
\hline
Point Poisson kriging (adjacent counties) & 7.835 & 2.542 & 1.006 & 0.338 \\
\hline
ATA Poisson kriging (adjacent counties) & 7.563 & 2.363 & 0.977 & 0.287 \\
\hline
ATA Poisson kriging (32 neighbors) & 7.400 & 2.297 & 0.830 & 0.237 \\
\hline
\end{tabular}}
\end{table}
|
PMC2276482_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{2}{|l|}{\textbf{Significance}} \\
\hline
\textbf{Muscle Total CoQ10 (mcg/mg) T2 pre ¥} & \textbf{r value} & \textbf{0.423} \\
\hline
& p value & 0.007 \\
\hline
Muscle Total CoQ10 (mcg/mg) T2 post & r value & 0.189 \\
\hline
& p value & 0.250 \\
\hline
Muscle Total CoQ10 (mcg/mg) T3 pre & r value & 0.247 \\
\hline
& p value & 0.125 \\
\hline
Muscle Total CoQ10 (mcg/mg) T3 post & r value & 0.244 \\
\hline
& p value & 0.134 \\
\hline
Oxygen Consumption (mL·kg-1·min-1) T1 ¥ & r value & 0.389 \\
\hline
& p value & 0.013 \\
\hline
Oxygen Consumption (mL·kg-1·min-1) T2 ¥ & r value & 0.381 \\
\hline
& p value & 0.017 \\
\hline
Oxygen Consumption (mL·kg-1·min-1) T3 ¥ & r value & 0.429 \\
\hline
& p value & 0.006 \\
\hline
Time to exhaustion (Min) T1 ¥ & r value & 0.419 \\
\hline
& p value & 0.007 \\
\hline
Time to exhaustion (Min) T2 ¥ & r value & 0.454 \\
\hline
& p value & 0.004 \\
\hline
Time to exhaustion (Min) T3 ¥ & r value & 0.485 \\
\hline
& p value & 0.001 \\
\hline
\end{tabular}}
\end{table}
|
PMC2315638_table_7
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Coding regions} & \textbf{Number of genotypes} & \textbf{Minimum intragenotype similarity} & \textbf{Maximum intergenotype similarity} \\
\hline
N & 8* & 83,3 & 80,3 \\
\hline
& 7 & 80,3 & 79,8 \\
\hline
N,P,M,G,L & 8* & 81,6 & 76,4 \\
\hline
& 7 & 76,3 & 76,4 \\
\hline
\end{tabular}}
\end{table}
|
PMC2327259_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& & \textbf{N} & \textbf{Ne} & \textbf{H} & \textbf{He} \\
\hline
MCL1 & real time RT-PCR & 1 & 2.97 & 5.53 & 8.24 \\
\hline
& DNA microarray & 1 & 3.44 & 3.92 & 5.27 \\
\hline
BAK 1 & real time RT-PCR & 1 & 3.37 & 0.96 & 2.92 \\
\hline
& DNA microarray & 1 & 3.42 & 0.75 & 2.13 \\
\hline
GPX1 & real time RT-PCR & 1 & 4.04 & 0.94 & 2.21 \\
\hline
& DNA microarray & 1 & 2.88 & 0.69 & 1.43 \\
\hline
CDKN1A & real time RT-PCR & 1 & 3.65 & 0.72 & 2.44 \\
\hline
& DNA microarray & 1 & 3.02 & 0.52 & 1.64 \\
\hline
JUN & real time RT-PCR & 1 & 1.45 & 5.54 & 4.36 \\
\hline
& DNA microarray & 1 & 1.66 & 2.33 & 3.28 \\
\hline
\end{tabular}}
\end{table}
|
PMC2330149_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Step} & \textbf{No. SNPs} & \textbf{0} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{6} & \textbf{7} & \textbf{8} & \textbf{9} & \textbf{$\geq$10} \\
\hline
1 & Availablea & 1286 & 413 & 310 & 614 & 417 & 148 & 169 & 59 & 16 & 16 & 14 \\
\hline
& AICb & 1286 & 1697 & 350 & 107 & 17 & 3 & 1 & 1 & 0 & 0 & 0 \\
\hline
& $\leq$ p 0.01c & & 245 & 43 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\
\hline
& $\leq$ p 0.001c & & 88 & 5 & 0 & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\
\hline
3 & Linkagesd & 294 & 81 & 76 & 118 & 141 & 102 & 101 & 102 & 110 & 91 & 2264 \\
\hline
& AIC & 294 & 664 & 362 & 295 & 270 & 236 & 187 & 147 & 127 & 101 & 645 \\
\hline
& $\leq$ p 0.01c & & 930 & 433 & 188 & 101 & 58 & 38 & 21 & 11 & 11 & 32 \\
\hline
& $\leq$ p 0.001c & & 572 & 151 & 60 & 25 & 12 & 10 & 3 & 6 & 2 & 2 \\
\hline
\end{tabular}}
\end{table}
|
PMC2367558_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Genotypes} & \multicolumn{2}{|l|}{\textbf{Controls}} & \multicolumn{2}{|l|}{\textbf{All Patients}} & & & \multicolumn{4}{|l|}{\textbf{Premenopausal Patients}} & \multicolumn{4}{|l|}{\textbf{Postmenopausal Patients}} \\
\hline
& \textbf{n} & \textbf{f} & \textbf{n} & \textbf{f} & \textbf{P} & \textbf{OR (95\%CI)} & \textbf{n} & \textbf{f} & \textbf{p} & \textbf{OR (95\%CI)} & \textbf{n} & \textbf{f} & \textbf{p} & \textbf{OR (95\%CI)} \\
\hline
CYP2E1 (C-1091T) & 244 & & 304 & & & & 192 & & & & 111 \\
\hline
CYP2E1 (C/C) & 232 & 0.95 & 296 & 0.97 & N.S & 1.91(0.72–5.22) & 186 & 0.97 & N.S & 1.6(0.55–4.89) & 109 & 0.98 & N.S & 2.82 (0.58–18.57) \\
\hline
CYP2E1 (C/T) & 12 & 0.05 & 08 & 0.03 & N.S & 0.52(0.19–1.4) & 06 & 0.03 & N.S & 0.62(0.2–1.83) & 02 & 0.02 & N.S & 0.35 (0.05–1.71) \\
\hline
CYP2E1 (T/T) & 00 & 0.00 & 00 & 0.00 & N.S & - & 00 & 0.00 & N.S & - & 00 & 0.00 & N.S & - \\
\hline
CYP2C19 (exon5 G-A) & 240 & & 304 & & & & 193 & & & & 109 \\
\hline
CYP2C19 (G/G) & 197 & 0.822 & 239 & 0.787 & N.S & 0.8(0.51–1.26) & 155 & 0.804 & N.S & 0.89(0.53–1.49) & 83 & 0.762 & N.S & 0.7 (0.39–1.25) \\
\hline
CYP2C19 (A/G) & 41 & 0.170 & 61 & 0.200 & N.S & 1.22(0.77–1.93) & 37 & 0.191 & N.S & 1.15(0.68–1.94) & 23 & 0.211 & N.S & 1.30 (0.71–2.38) \\
\hline
CYP2C19 (A/A) & 02 & 0.008 & 04 & 0.013 & N.S & 1.59(0.25–12.56) & 01 & 0.005 & N.S & 0.62(0.02–8.76) & 03 & 0.027 & N.S & 3.37 (0.45–29.24) \\
\hline
CYP2D6 (G1934A) & 230 & & 300 & & & & 189 & & & & 109 \\
\hline
CYP2D6 (G/G) & 167 & 0.726 & 235 & 0.783 & N.S & 1.36(0.9–2.07) & 145 & 0.767 & N.S & 1.24(0.78–1.99) & 90 & 0.827 & 0.04 & 1.79 (0.97–3.31) \\
\hline
CYP2D6 (G/A) & 56 & 0.243 & 58 & 0.193 & N.S & 0.74(0.48–1.15) & 41 & 0.217 & N.S & 0.86(0.53–1.42) & 15 & 0.137 & 0.02 & 0.5 (0.25–0.96) \\
\hline
CYP2D6 (A/A) & 07 & 0.031 & 07 & 0.023 & N.S & 0.76(0.24–2.48) & 03 & 0.016 & N.S & 0.51(0.1–2.24) & 04 & 0.036 & N.S & 1.21 (0.29–4.74) \\
\hline
mEH (T348C) & 244 & & 306 & & & & 194 & & & & 110 \\
\hline
mEH1 (Tyr/Tyr) & 113 & 0.463 & 149 & 0.486 & N.S & 1.1(0.77–1.56) & 97 & 0.500 & N.S & 1.16(0.78–1.72) & 52 & 0.472 & N.S & 1.04 (0.65–1.67) \\
\hline
mEH2 (Tyr/His) & 115 & 0.471 & 119 & 0.388 & N.S & 0.71(0.5–1.02) & 70 & 0.360 & 0.02 & 0.63(0.42–0.95) & 47 & 0.427 & N.S & 0.84 (0.52–1.35) \\
\hline
mEH3 (His/His) & 16 & 0.065 & 38 & 0.124 & 0.02 & 2.02(1.06–3.89) & 27 & 0.139 & 0.01 & 2.3(1.15–4.64) & 11 & 0.1 & N.S & 1.58 (0.66–3.77) \\
\hline
NAT2 & 237 & & 290 & & & & 184 & & & & 105 \\
\hline
Rapid Acetylators & 14 & 0.059 & 24 & 0.082 & N.S & 1.44(0.69–3) & 18 & 0.097 & N.S & 1.73(0.79–3.79) & 06 & 0.057 & N.S & 0.97 (0.32–2.79) \\
\hline
Intermediate Acetylators & 105 & 0.443 & 92 & 0.317 & N.S & 0.58(0.4–0.85) & 61 & 0.331 & N.S & 0.62(0.41–0.95) & 30 & 0.285 & 0.006 & 0.52 (0.3–0.85) \\
\hline
Slow Acetylators & 118 & 0.497 & 174 & 0.600 & 0.01 & 1.51(1.05–2.17) & 105 & 0.570 & N.S & 1.34(0.89–2.01) & 69 & 0.657 & 0.006 & 1.93 (1.17–3.2) \\
\hline
\end{tabular}}
\end{table}
|
PMC2377277_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Study} & \textbf{Outcome} & \textbf{Relative Risk/Incident Density Ratio (95\% CI)} \\
\hline
Luby, Agboatwalla et al 2004 [50] & Diarrhoea \\
\hline
RCT & Mean Incidence \\
\hline
Quality Score 6a & Antibiotic Soap & 0.50 (0.36, 0.63) \\
\hline
& Plain Soap & 0.47 (0.35, 0.59) \\
\hline
Shahid, Greenough et al 1996 [43] & Diarrhoea \\
\hline
CBA & Age groups \\
\hline
Quality Score 1b & 0 – 11 mths & 0.39 (0.29, 0.54) \\
\hline
& 12–23 mths & 0.53 (0.37, 0.77) \\
\hline
& 24–59 mths & 0.44 (0.34, 0.59) \\
\hline
& 6 – 9 yrs & 0.27 (0.19, 0.37) \\
\hline
& 10 – 14 yrs & 0.28 (0.16, 0.49) \\
\hline
& Over 15 yrs & 0.38 (0.30, 0.49) \\
\hline
& All & 0.38 (0.33, 0.43) \\
\hline
Wilson, Chandler et al 1991 [51] & Diarrhoea \\
\hline
CBA & Children $<$11yrs & 0.21 (0.08, 0.53)c \\
\hline
Quality Score 3b & Skin/Eye Disease \\
\hline
& Children $<$11yrs & 2.54d \\
\hline
Han, Hlaing et al 1988, 1989 [36] & Ascaris \\
\hline
RCT & Children 36–59mths & 1.0d \\
\hline
Quality Score 4a & Diarrhoea \\
\hline
& $<$2yrs & 0.69 (0.48, 1.01)e \\
\hline
& $\geq$ 2yrs & 0.67 (0.45, 0.98)e \\
\hline
& All children $<$5yrs & 0.70 (0.54, 0.92)f \\
\hline
& Dysentery \\
\hline
& $<$2yrs & 0.59 (0.22, 1.55) \\
\hline
& $\geq$ 2yrs & 1.21 (0.52, 2.80) \\
\hline
& All children $<$5yrs & 0.93 (0.39, 2.23) \\
\hline
\end{tabular}}
\end{table}
|
PMC2397399_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Strain (a)} & \textbf{Mic-PCC7806} & \textbf{Mic-NIES843} \\
\hline
Genome length & 5.17 Mb (116 Contigs) & 5.84 Mb \\
\hline
rRNA loci & 2 & 2 \\
\hline
tRNA loci & 41 & 42 \\
\hline
Number of CDSs & 5292 & 6312 \\
\hline
Putative transposases (COG similarity) & 362 (6.8\%) & 469 (7.4\%) \\
\hline
Proteins linked by BDBH & 3322 (63\%) & 3322 (53\%) \\
\hline
Proteins absent in the other Microcystis genome (b) & 838 (16\%) & 1760 (28\%) \\
\hline
Strain-specific proteins (c) & 644/838 (76\%) & 1484/1760 (84\%) \\
\hline
Large repeats (d) & 11.7\% & 11.7\% \\
\hline
\end{tabular}}
\end{table}
|
PMC2442094_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{Lbx1/Tlx1 locus} & \textbf{Former Lbx4/Tlx4 locus} & \textbf{(Former Lbx3)/Tlx3 locus} & \textbf{Lbx2/Tlx2 locus} & \textbf{Lbx-less Nkx3.2 locus} & \textbf{Lbx2/Tlx2 loci} \\
\hline
& & & & amniotes & tetrapods & teleosts \\
\hline
Msx & & & Msx2 \\
\hline
Nkx2/tin & Nkx2.3 & Nkx2.6 & Nkx2.5 \\
\hline
Nkx3/bap & & Nkx3.1 & & & Nkx3.2 & Nkx3.2 \\
\hline
& & (chicken: Nkx2.8 only) \\
\hline
Nkx6 & & Nkx6.3 \\
\hline
Lbx & Lbx1 & & & Lbx2 & & Lbx2 \\
\hline
Tlx & Tlx1 & & Tlx3 & Tlx2 & & Tlx2 \\
\hline
Pol & Poll & Polb \\
\hline
Dpcd & Dpcd \\
\hline
Fbxw4 & Fbxw4 \\
\hline
Fbxw7 & & & & & Fbxw7 & Fbxw7 \\
\hline
Slc2a15 & Slc2a15 & & & & Slc2a9 (tetrapods) \\
\hline
Aup & & & & Aup1 & & Aup1 \\
\hline
Pcgf1 & & & & Pcgf1 & & Pcgf1 \\
\hline
Fbxw11/Btrc & Btrc & & Fbxw11/Btrc2 \\
\hline
Mgea & Mgea5 & & & Mgea2 (chicken) & & Mgea2 \\
\hline
Kazald & Kazald1 (tetrapods) & Kazald3 (fish) & & Kazald2 (zebrafish) \\
\hline
Ldb & Ldb1 & & & & Ldb2 & Ldb2 \\
\hline
Prom & Prom3 (fish) & Prom2 (tetrapods)* & & & Prom1 & Prom1 \\
\hline
Loxl & Loxl4 & Loxl2 & & Loxl3 & & Loxl3 \\
\hline
Slit & Slit1 & & Slit3 & & Slit2 & Slit2 \\
\hline
Dok & & Dok2 & Dok3 & Dok1 & & Dok1 \\
\hline
Fgf & Fgf8 & Fgf17 & Fgf18 & & & Fgf24 \\
\hline
Npm & Npm3 & Npm2 & Npm1 & & & Npm4 \\
\hline
Kcnip & Kcnip2 & Kcnip3* & Kcnip1 & & Kcnip4 & Kcnip4 \\
\hline
\end{tabular}}
\end{table}
|
PMC2446394_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Characteristic} & \textbf{n (\%)a} \\
\hline
\multicolumn{2}{|l|}{Sex} \\
\hline
Male & 234 (55.7) \\
\hline
Female & 186 (44.3) \\
\hline
Age (years) & 68.2 $\pm$ 13.8 \\
\hline
$<$ 65 & 138 (32.9) \\
\hline
65–79 & 198 (47.1) \\
\hline
$\geq$ 80 & 84 (20.0) \\
\hline
History of previous stroke (n = 418) & 109 (26.1) \\
\hline
Length of hospital stay (days) & 16.2 $\pm$ 21.1 \\
\hline
\multicolumn{2}{|l|}{Stroke subtype} \\
\hline
Partial anterior circulation & 132 (31.4) \\
\hline
Lacunar & 106 (25.2) \\
\hline
Posterior circulation & 79 (18.8) \\
\hline
Total anterior circulation & 30 (7.1) \\
\hline
Transient ischemic attack & 59 (14.0) \\
\hline
Uncertain & 14 (3.3) \\
\hline
\multicolumn{2}{|l|}{Stroke severity} \\
\hline
Transient ischemic attack & 35 (8.4) \\
\hline
Mild & 90 (21.5) \\
\hline
Moderate & 226 (53.9) \\
\hline
Severe & 68 (16.2) \\
\hline
Unknown & 1 (0.002) \\
\hline
\multicolumn{2}{|l|}{Disability at discharge} \\
\hline
Independent & 333 (79.3) \\
\hline
Dependent & 87 (20.7) \\
\hline
\multicolumn{2}{|l|}{Cognitive impairment at discharge} \\
\hline
Not impaired & 111 (26.4) \\
\hline
Impaired & 84 (20.0) \\
\hline
Missing & 225 (53.6) \\
\hline
Atrial fibrillation (n = 418) & 60 (14.4) \\
\hline
Average household income (n = 386) & \$55,472 $\pm$ 19,370 \\
\hline
Total medications prescribedb & 6.4 $\pm$ 2.6 \\
\hline
Total doses taken per dayb & 8.6 $\pm$ 4.5 \\
\hline
Monthly cost of prescription drugsc & \$167.10 $\pm$ 99.47 \\
\hline
\end{tabular}}
\end{table}
|
PMC2474854_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Parameter [statistic]} & \textbf{All patients} & \multicolumn{3}{|l|}{\textbf{Olanzapine vs. non-olanzapine}} & \multicolumn{3}{|l|}{\textbf{Risperidone vs. non-risperidone}} & \multicolumn{3}{|l|}{\textbf{Haloperidol vs. non-haloperidol}} \\
\hline
& & \textbf{OLZ (N = 390)} & \textbf{Non-OLZ (N = 168)} & \textbf{p-value} & \textbf{RIS (N = 72)} & \textbf{Non-RIS (N = 486)} & \textbf{p-value} & \textbf{HAL (N = 132)} & \textbf{Non-HAL (N = 426)} & \textbf{p-value} \\
\hline
& \textbf{(N = 558)} \\
\hline
\multicolumn{11}{|l|}{Previous pharmacological treatmenta} \\
\hline
Any previous medication n (\%) & 291 (52.2) & 191 (49.0) & 100 (59.5) & 0.022 & 45 (62.5) & 246 (50.6) & 0.060 & 64 (48.5) & 227 (53.3) & 0.335 \\
\hline
Any antipsychotic n (\%) & 214 (38.4) & 130 (33.3) & 84 (50.0) & $<$ .001 & 38 (52.8) & 176 (36.2) & 0.007 & 52 (39.4) & 162 (38.0) & 0.778 \\
\hline
Olanzapine, n (\%) & 52 (9.3) & 48 (12.3) & 4 (2.4) & & 5 (6.9) & 47 (9.7) & & 13 (9.8) & 39 (9.2) \\
\hline
Risperidone, n (\%) & 50 (9.0) & 26 (6.7) & 24 (14.3) & & 30 (41.7) & 20 (4.1) & & 11 (8.3) & 39 (9.2) \\
\hline
Haloperidol, n (\%) & 45 (8.1) & 30 (7.7) & 15 (8.9) & & 5 (6.9) & 40 (8.2) & & 25 (18.9) & 20 (4.7) \\
\hline
Quetiapine, n (\%) & 19 (3.4) & 6 (1.5) & 13 (7.7) & & 0 (0.0) & 19 (3.9) & & 4 (3.0) & 15 (3.5) \\
\hline
Any benzodiazepine n (\%) & 106 (19.0) & 75 (19.2) & 31 (18.5) & 0.830 & 10 (13.9) & 96 (19.8) & 0.236 & 22 (16.7) & 84 (19.7) & 0.435 \\
\hline
Lorazepam, n (\%) & 51 (9.1) & 36 (9.2) & 15 (8.9) & & 6 (8.3) & 45 (9.3) & & 14 (10.6) & 37 (8.7) \\
\hline
Diazepam, n (\%) & 43 (7.7) & 29 (7.4) & 14 (8.3) & & 3 (4.2) & 40 (8.2) & & 7 (5.3) & 36 (8.5) \\
\hline
Mood stabilizer n (\%) & 67 (12.0) & 48 (12.3) & 19 (11.3) & 0.939 & 7 (9.7) & 60 (12.3) & 0.568 & 11 (8.3) & 56 (13.1) & 0.141 \\
\hline
Antidepressants n (\%) & 64 (11.5) & 47 (12.1) & 17 (10.1) & 0.679 & 8 (11.1) & 56 (11.5) & 0.976 & 9 (6.8) & 55 (12.9) & 0.056 \\
\hline
Antipsychotic monotherapy n (\%) & 227 (40.7) & 183 (46.9) & 44 (26.2) & $<$ .001 & 13 (18.1) & 214 (44.0) & $<$ .001 & 11 (8.3) & 216 (50.7) & $<$ .001 \\
\hline
\multicolumn{11}{|l|}{Concomitant benzodiazepine use} \\
\hline
Any benzodiazepine use n (\%) [95\% CI (\%)] & 389 (69.7) [65.7–73.5] & 268 (68.7) [63.9–73.3] & 121 (72.0) [64.6–78.7] & 0.436 & 52 (72.2) [60.4–82.1] & 337 (69.3) [65.0–73.4] & 0.620 & 110 (83.3) [75.9–89.3] & 279 (65.5) [60.8–70.0] & $<$ .001 \\
\hline
Lorazepam, n (\%) & 248 (44.4) & 177 (45.4) & 71 (42.3) & & 35 (48.6) & 213 (43.8) & & 65 (49.2) & 183 (43.0) \\
\hline
Diazepam, n (\%) & 175 (31.4) & 109 (27.9) & 66 (39.3) & & 29 (40.3) & 146 (30.0) & & 75 (56.8) & 100 (23.5) \\
\hline
Other, n (\%) & 64 (11.5) & 38 (9.7) & 26 (15.5) & & 12 (16.7) & 52 (10.7) & & 12 (9.1) & 52 (12.2) \\
\hline
Benzodiazepine doseb mean (SD), mg & 81.3 (58.1) & 77.9 (52.5) & 89.0 (68.5) & 0.081 & 86.4 (72.5) & 80.6 (55.6) & 0.497 & 76.4 (50.6) & 83.3 (60.8) & 0.296 \\
\hline
\end{tabular}}
\end{table}
|
PMC2507712_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Risk of dissatisfaction} & \textbf{Public (\%)} & \textbf{Private (\%)} & \textbf{All (\%)} \\
\hline
Properly identified specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\
\hline
Clear and accurate test request & 4/10 (40.0) & 2/4(50.0) & 6/14(42.9) \\
\hline
Properly collected and transported specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\
\hline
Availability of equipment & 4/10 (40.0) & 1/4(25.0) & 5/14(35.7) \\
\hline
Communication between laboratories & 4/10 (40.0) & 2/4(50.0) & 6/14(42.9) \\
\hline
Timely results feed back to the sending laboratory & 1/10(10.0) & 1/4(25.0) & 2/14(14.5) \\
\hline
\end{tabular}}
\end{table}
|
PMC2518553_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Gene Category} & \textbf{Genes Upregulated} & \textbf{Genes Downregulated} \\
\hline
Protein Transport & 6 & 2 \\
\hline
Ion Transport & 6 & 3 \\
\hline
Proliferation & 2 & 2 \\
\hline
Differentiation & 2 & 2 \\
\hline
Anti-apoptosis/Survival & 3 & 1 \\
\hline
Transcription & 10 & 4 \\
\hline
Metabolism & 5 & 6 \\
\hline
Structural & 5 & 4 \\
\hline
Adhesion & 4 & 1 \\
\hline
Protein Synthesis & 7 & 0 \\
\hline
Immune Response \& Inflammation & 4 & 1 \\
\hline
Signal Transduction & 5 & 3 \\
\hline
Cell Cycle \& DNA repair & 5 & 2 \\
\hline
Miscellaneous & 3 & 4 \\
\hline
\end{tabular}}
\end{table}
|
PMC2533024_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Species} & \textbf{# genes amplified1} & \textbf{# disrupted genes} & \textbf{\% disrupted} \\
\hline
A449 & 162 & 16 & 100 \\
\hline
A449 cDNA & 16 & 16 & 100 \\
\hline
A. salmonicida subsp. salmonicida ATCC 33658T & 15 & 15 & 100 \\
\hline
subsp. ATCC 51413 (non-pigmented) A. salmonicida salmonicida & 16 & 16 & 100 \\
\hline
A. salmonicida subsp. masoucida ATCC 27013T & 13 & 3 & 23 \\
\hline
A. salmonicida subsp. achromogenes ATCC 33659T & 14 & 3 & 21 \\
\hline
A. salmonicida subsp. smithia ATCC 49393T & 15 & 4 & 27 \\
\hline
A. bestarium ATCC 51108T & 7 & 0 & 0 \\
\hline
A. veronii bv. sobria ATCC 9071 & 4 & 0 & 0 \\
\hline
A. sobria ATCC 43979T & 2 & 0 & 0 \\
\hline
A. caviae ATCC 15468T & 2 & 0 & 0 \\
\hline
A. hydrophila ATCC 7966T & 132 & 0 & 0 \\
\hline
\end{tabular}}
\end{table}
|
PMC2556355_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Characteristic} & \textbf{PD (n = 57)} & \textbf{Controls (n = 51)} \\
\hline
Age at study (mean6SD), years & 62.369.1 & 63.768.7 \\
\hline
(mean6SD), Age at onset years & 58.269.1 & N/A \\
\hline
Range of age at onset, years & 40–75 & N/A \\
\hline
Onset before age 50, n (\%) & 7 (12.3) & N/A \\
\hline
Asymmetry of tremors or rigidity at onset, n (\%) & 57 (100) & N/A \\
\hline
Bradykinesia, n (\%) & 57 (100) & N/A \\
\hline
Parkinsonian tremor, n (\%) & 57 (100) & N/A \\
\hline
Rigidity, n (\%) & 57 (100) & N/A \\
\hline
Postural abnormality, n (\%) & 31 (54.4) & N/A \\
\hline
Gait abnormality, n (\%) & 48 (84.2) & N/A \\
\hline
Levodopa responsiveness, n (\%)* & 54 (94.7) & N/A \\
\hline
MMSE [mean6SD (range)] & 28.362.1 (19–30) & N/A \\
\hline
Hoehn \& Yahr stage [median (range)] & 2 (1–4) & N/A \\
\hline
[mean6SD UPDRS - motor subscale (range)] & 35.1612.6 (10–66) & N/A \\
\hline
Family history of tremors in a first-degree relative, n (\%) & 9 (15.8) & N/A \\
\hline
\end{tabular}}
\end{table}
|
PMC2559870_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Stage of labour} & \textbf{Definition of stage and phase} & \textbf{Diagnostic Criteria for Dystocia} \\
\hline
First stage & From onset of regular contractions leading to cervical dilatation to full dilatation of cervix \\
\hline
Latent phase & Cervix 0 – 3.9 cm dilatation & The diagnosis was not to be given in this phase \\
\hline
Active phase & $\geq$ Cervix 4 cm dilatation & $<$ 1/2 cm dilatation of cervix per hour, assessed over 4 hours = dystocia \\
\hline
Second stage & From full dilatation of cervix to the child is born \\
\hline
Descending phase & From full dilatation of cervix to strong and irresistible urge to push & $>$ 2 hours without descent = dystocia. If epidural is administered: $>$ 3 hours = dystocia \\
\hline
Expulsive phase & Strong and irresistible pushing during the major part of the contraction & $>$ 1 hour without progress = dystocia \\
\hline
\end{tabular}}
\end{table}
|
PMC2569907_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Lipid variable} & \textbf{Educational status} & \textbf{Obesity} & \textbf{Truncal obesity} \\
\hline
$\geq$ Total Cholesterol 200 mg/dl & 0.450 (0.072) & 0.322 (0.120) & 0.773 (0.011) \\
\hline
$\geq$ LDL Cholesterol 130 mg/dl & 0.529 (0.051) & 0.462 (0.069) & 0.737 (0.014) \\
\hline
HDL Cholesterol $<$ 40 mg/dl & 0.347 (0.109) & 0.352 (0.107) & 0.477 (0.064) \\
\hline
$\geq$ Non-HDL Cholesterol 160 mg/dl & 0.531 (0.050) & 0.421 (0.082) & 0.884 (0.003) \\
\hline
$\geq$ Remnant cholesterol 25 mg/dl & -0.211 (0.179) & -0.257 (0.152) & -0.0711 (0.305) \\
\hline
$\geq$ Total:HDL cholesterol ratio 5.0 & 0.469 (0.067) & 0.456 (0.071) & 0.593 (0.037) \\
\hline
$\geq$ Total:HDL cholesterol ratio 4.0 & 0.535 (0.049) & 0.480 (0.061) & 0.768 (0.011) \\
\hline
$\geq$ Triglycerides 150 mg/dl & -0.111 (0.259) & -0.196 (0.189) & 0.099 (0.272) \\
\hline
\end{tabular}}
\end{table}
|
PMC2579290_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Analyses} & \textbf{Dose Group} & \multicolumn{3}{|l|}{\textbf{Proportion of Responders}} & \multicolumn{2}{|l|}{\textbf{SBA Titers four weeks after vaccination}} \\
\hline
& & \textbf{n/N} & \textbf{\%} & \textbf{95\% CI} & \textbf{GMT} & \textbf{95\% CI} \\
\hline
\multicolumn{7}{|l|}{Serogroup A} \\
\hline
MITT & Full & 249/289 & 86.2 & 82.2–90.2 & 3607.1 & 2952.8–4406.3 \\
\hline
& 1/5 dose & 173/224 & 77.2 & 71.7–82.7 & 2035.4 & 1600.1–2589.0 \\
\hline
& 1/10 dose & 159/230 & 69.1 & 63.2 -75.0 & 1367.6 & 1083.1–1726.8 \\
\hline
PP & Full & 247/287 & 86.1 & 82.1–90.1 & 3612.6 & 2953.3–4419.1 \\
\hline
& 1/5 dose & 172/222 & 77.5 & 72.0–83.0 & 2054.4 & 1612.2–2618.0 \\
\hline
& 1/10 dose & 159/229 & 69.4 & 63.5–75.3 & 1369.3 & 1083.3–1730.7 \\
\hline
Non immune & Full & 140/148 & 94.6 & 91.0–98.2 & 1918.0 & 1426.0–2579.8 \\
\hline
& 1/5 dose & 94/102 & 92.2 & 87.0–97.4 & 852.3 & 573.2–1267.5 \\
\hline
& 1/10 dose & 98/111 & 88.3 & 82.4–94.2 & 754.1 & 495.3–1148.1 \\
\hline
\multicolumn{7}{|l|}{Serogroup W135} \\
\hline
MITT & Full & 269/289 & 93.1 & 90.2–96.0 & 2190.3 & 1728.9–2774.6 \\
\hline
& 1/5 dose & 212/224 & 94.6 & 91.7–97.5 & 2029.1 & 1573.7–2616.2 \\
\hline
& 1/10 dose & 220/231 & 95.2 & 92.5–97.9 & 2422.7 & 1979.9–2964.6 \\
\hline
PP & Full & 267/286 & 93.4 & 90.5–96.3 & 2175.9 & 1714.2–2762.0 \\
\hline
& 1/5 dose & 210/222 & 94.6 & 91.6–97.6 & 2041.6 & 1582.2–2634.5 \\
\hline
& 1/10 dose & 219/229 & 95.6 & 93.0–98.2 & 2426.3 & 1979.7–2973.7 \\
\hline
Non immune & Full & 207/221 & 93.7 & 90.5–96.9 & 1539.5 & 1160.0–2043.2 \\
\hline
& 1/5 dose & 168/178 & 94.4 & 91.0–97.8 & 1517.4 & 1129.3–2039.0 \\
\hline
& 1/10 dose & 172/177 & 97.2 & 94.8–99.6 & 2008.3 & 1583.0–2547.9 \\
\hline
\multicolumn{7}{|l|}{Serogroup C} \\
\hline
MITT & Full & 259/284 & 91.2 & 87.9–94.5 & 1168.3 & 911.0–1498.2 \\
\hline
& 1/5 dose & 179/222 & 80.6 & 75.4–85.8 & 472.1 & 332.3–670.6 \\
\hline
& 1/10 dose & 171/223 & 76.7 & 71.2–82.2 & 399.3 & 277.1–575.4 \\
\hline
PP & Full & 257/282 & 91.1 & 87.8–94.4 & 1175.1 & 914.9–1509.3 \\
\hline
& 1/5 dose & 177/220 & 80.4 & 75.2–85.6 & 467.3 & 328.0–665.8 \\
\hline
& 1/10 dose & 170/222 & 76.6 & 71.1–82.1 & 396.3 & 274.6–572.0 \\
\hline
Non immune & Full & 252/271 & 93.0 & 90.0–96.0 & 1108.5 & 858.4–1431.5 \\
\hline
& 1/5 dose & 172/211 & 81.5 & 76.3–86.7 & 412.2 & 288.2–589.6 \\
\hline
& 1/10 dose & 156/202 & 77.2 & 71.4–83.0 & 315.6 & 214.8–463.8 \\
\hline
\multicolumn{7}{|l|}{Serogroup Y} \\
\hline
MITT & Full & 242/286 & 84.6 & 80.4–88.8 & 936.2 & 673.7–1301.0 \\
\hline
& 1/5 dose & 185/224 & 82.6 & 77.7–87.5 & 772.7 & 529.2–1128.2 \\
\hline
& 1/10 dose & 194/231 & 84.0 & 79.3–88.7 & 822.6 & 569.8–1187.5 \\
\hline
PP & Full & 240/284 & 84.5 & 80.3–88.7 & 924.2 & 663.8–1286.7 \\
\hline
& 1/5 dose & 183/222 & 82.4 & 77.4–87.4 & 768.3 & 524.4–1125.6 \\
\hline
& 1/10 dose & 193/230 & 83.9 & 79.2–88.6 & 816.8 & 565.1–1180.8 \\
\hline
Non immune & Full & 238/282 & 84.4 & 80.2–88.6 & 916.8 & 657.3–1278.8 \\
\hline
& 1/5 dose & 175/214 & 81.8 & 76.7–86.9 & 687.5 & 466.1–1014.1 \\
\hline
& 1/10 dose & 191/228 & 83.8 & 79.0–88.6 & 798.1 & 551.1–1155.7 \\
\hline
\end{tabular}}
\end{table}
|
PMC2584372_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Substance} & \textbf{Sham} & \textbf{Saline} & \textbf{LPS} & \textbf{Kruskal-Wallis H(2, N = 33)} \\
\hline
\multicolumn{5}{|l|}{Alkanes} \\
\hline
Octadecane & 0,17 $\pm$ 0,11 & 0,18 $\pm$ 0,05 & 0,19 $\pm$ 0,11 & NS \\
\hline
Nonadecane & 0,29 $\pm$ 0,14 & 0,35 $\pm$ 0,21 & 0,15 $\pm$ 0,04 & NS \\
\hline
Eicosane & 0,09 $\pm$ 0,04 & 0,09 $\pm$ 0,03 & 0,06 $\pm$ 0,04 & NS \\
\hline
Heneicosane & 1,24 $\pm$ 0,40 & 1,73 $\pm$ 0,65 & 0,84 $\pm$ 0,20 & NS \\
\hline
Docosane & 0,14 $\pm$ 0,02 & 0,16 $\pm$ 0,04 & 0,11 $\pm$ 0,02 & NS \\
\hline
Tricosane & 4,42 $\pm$ 0,73 & 4,70 $\pm$ 0,89 & 3,92 $\pm$ 0,39 & NS \\
\hline
Tetracosane & tr & tr & tr & NS \\
\hline
Pentacosane & 2,88 $\pm$ 0,66 & 2,76 $\pm$ 0,16 & 2,99 $\pm$ 0,17 & NS \\
\hline
Hexacosane & 0,38 $\pm$ 0,13 & 0,38 $\pm$ 0,07 & 0,34 $\pm$ 0,04 & NS \\
\hline
Heptacosane & 10,21 $\pm$ 3,91 & 9,76 $\pm$ 1,76 & 9,88 $\pm$ 1,45 & NS \\
\hline
Octacosane & 0,67 $\pm$ 0,06 & 0,62 $\pm$ 0,04 & 0,59 $\pm$ 0,06 & NS \\
\hline
Nonacosane & 14,15 $\pm$ 0,83 & 12,56 $\pm$ 1,52 & 12,33 $\pm$ 1,12 & NS \\
\hline
Tritriacontane & 0,72 $\pm$ 0,15 & 0,76 $\pm$ 0,06 & 0,77 $\pm$ 0,06 & NS \\
\hline
Hentriacontane & 17,24 $\pm$ 3,59 & 17,49 $\pm$ 1,99 & 18,70 $\pm$ 1,12 & NS \\
\hline
Dotriacontane & 0,23 $\pm$ 0,06 & 0,30 $\pm$ 0,08 & 0,30 $\pm$ 0,07 & p = 0.05 \\
\hline
Tritriacontane & 3,03 $\pm$ 0,93 & 4,60 $\pm$ 1,51 & 4,51 $\pm$ 1,00 & p = 0.024 \\
\hline
\multicolumn{5}{|l|}{Alkenes} \\
\hline
Nonadecene & tr & tr & tr & NS \\
\hline
Tricosene & 0,30 $\pm$ 0,08 & 0,31 $\pm$ 0,06 & 0,29 $\pm$ 0,03 & NS \\
\hline
Pentacosene & 0,37 $\pm$ 0,06 & 0,35 $\pm$ 0,05 & 0,32 $\pm$ 0,03 & p = 0.049 \\
\hline
Heptacosene & 0,39 $\pm$ 0,11 & 0,36 $\pm$ 0,13 & 0,26 $\pm$ 0,04 & p = 0.001 \\
\hline
Nonacosene & 1,17 $\pm$ 0,09 & 0,96 $\pm$ 0,10 & 0,98 $\pm$ 0,08 & p = 0.014 \\
\hline
Hentriacontene Isomere1 & 4,42 $\pm$ 0,47 & 4,23 $\pm$ 0,21 & 4,37 $\pm$ 0,52 & NS \\
\hline
Hentriacontene Isomere 2 & 6,17 $\pm$ 0,52 & 6,06 $\pm$ 0,24 & 6,28 $\pm$ 0,61 & NS \\
\hline
Dotriacontene & 0,89 $\pm$ 0,12 & 0,98 $\pm$ 0,04 & 1,02 $\pm$ 0,08 & p = 0.026 \\
\hline
Tritriacontene & 16,77 $\pm$ 3,02 & 19,24 $\pm$ 0,49 & 20,30 $\pm$ 1,71 & p = 0.01 \\
\hline
\multicolumn{5}{|l|}{Alkynes} \\
\hline
Pentacosyne & tr & tr & tr & NS \\
\hline
Tritriacontyne & 2,08 $\pm$ 0,46 & 2,43 $\pm$ 0,83 & 2,44 $\pm$ 0,31 & NS \\
\hline
\multicolumn{5}{|l|}{Methylalkanes} \\
\hline
11,13,15-Methylpentacosane & 0,30 $\pm$ 0,07 & 0,29 $\pm$ 0,07 & 0,38 $\pm$ 0,04 & NS \\
\hline
11,13-Methylheptacosane & 2,39 $\pm$ 0,31 & 2,60 $\pm$ 0,58 & 2,50 $\pm$ 0,21 & NS \\
\hline
11,13,15-Methylnonacosane & 2,15 $\pm$ 0,19 & 2,34 $\pm$ 0,56 & 2,27 $\pm$ 0,24 & NS \\
\hline
11,13,15-Methylhentriacontane & 1,31 $\pm$ 0,12 & 1,43 $\pm$ 0,35 & 1,42 $\pm$ 0,15 & NS \\
\hline
11,13,15,17-Methyltritriacontane & 0,56 $\pm$ 0,07 & 0,68 $\pm$ 0,17 & 0,69 $\pm$ 0,08 & NS \\
\hline
\end{tabular}}
\end{table}
|
PMC2596086_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Species} & \textbf{Mineralization of the permanent dentition at birth} & \textbf{Reference} \\
\hline
\multicolumn{3}{|l|}{Category I. Altricial: eyes closed, naked, nidicolous or ‘nest-dwelling’} \\
\hline
Gray short-tail opossum, Monodelphis domestica & None & [33] \\
\hline
Brown bear, Ursus arctos & None & [22] \\
\hline
Indian mongoose, Herpestes auropunctatus & None & [34] \\
\hline
Ferret, Mustela putorious & None & [35] \\
\hline
Domestic dog, Canis familiaris & Trace & [36] \\
\hline
\multicolumn{3}{|l|}{Category II. Precocial: eyes open, haired, nidicolous or ‘nest-dwelling’} \\
\hline
Domestic pig, Sus scrofa & None & [37] \\
\hline
Miniature pig, Sus scrofa & M1 cusp tips beginning to mineralize & [38] \\
\hline
Collared peccary, Tayassu tajacu & M1 cusp tips formed & [39] \\
\hline
\multicolumn{3}{|l|}{Category III. Precocial: eyes open, haired, transported (largely primates)} \\
\hline
Human, Homo sapiens & M1 cusp tips beginning to mineralize & [40] \\
\hline
Great apes, Pan, Gorilla, and Pongo spp. & M1 cusp tips beginning to mineralize & [40] \\
\hline
Gibbon, Hylobates sp. & M1 cusp tips beginning to mineralize & [40] \\
\hline
Rhesus macaque, Macaca mulaltta & M1 cusp tips formed & [41] \\
\hline
Mongoose lemur, Eulemur mongoz & M1 cusp tips formed & [42] \\
\hline
Coquerel’s sifaka, Propithecus verreauxi & M1 crown almost complete, M2 near coalescence, M3 trace & [42] \\
\hline
Tarsier, Tarsius bancanus & M1 ‘well differentiated’ (some deciduous teeth resorbed in utero) & [43] \\
\hline
\multicolumn{3}{|l|}{Category IV. Precocial: eyes open, haired, nidifugous or ‘nest-fleeing’} \\
\hline
American tapir, Tapirus cf. T. bairdii & M1 anterior cusps connected & [44] \\
\hline
Domestic sheep, Ovis aries & M1 cusps connected; crown one-quarter formed & [45] \\
\hline
inuus1 Maiacetus & M1 crown one-half formed & this study \\
\hline
Fallow deer, Dama dama & M1 crown one-half formed & [46] \\
\hline
Pygmy hippo, Hexaprotodon liberensis & M1? (many deciduous teeth erupted at birth; large M1 crypt) & [27] \\
\hline
Giraffe, Giraffa camelopardalis & M1 crown complete (all deciduous teeth erupted at birth) & [47] \\
\hline
Fur seal, Callorhinus ursinus & M1-2 crowns complete (deciduous teeth shed in utero) & [48] \\
\hline
Guinea pig, Cavia porcellus & All permanent teeth erupted; roots incomplete & [23] \\
\hline
\end{tabular}}
\end{table}
|
PMC2629576_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Family} & \textbf{Members} \\
\hline
1 & mir-466b-1 mir-466b-2 \\
\hline
2 & mir-664-1 mir-664-2 \\
\hline
\end{tabular}}
\end{table}
|
PMC2632650_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Term} & \textbf{Description and synonyms} \\
\hline
LRTI & Lower respiratory tract infection. Used synonymously with pneumonia. Includes all cases identified as mild, severe or very severe pneumonia. \\
\hline
All-cause LRTI & Non-specific lower respiratory tract infection. \\
\hline
RSV-ARI & Clinical (i.e. symptomatic) RSV antigen positive episode. Irrespective of severity. \\
\hline
RSV-LRTI & RSV-associated LRTI (pneumonia) and equivalent to RSV disease. \\
\hline
Disease progression & Development of LRTI from upper respiratory tract infection. \\
\hline
\end{tabular}}
\end{table}
|
PMC2635480_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Experiment No.} & \textbf{Open circuit Voltage-V (Theoretical)} & \textbf{Open circuit Voltage-V ( Practical)} \\
\hline
EX1 & 1.198 & 0.386 \\
\hline
EX2 & 0.858 & 0.332 \\
\hline
EX3 & 1.219 & 0.327 \\
\hline
EX4 & 1.209 & 0.234 \\
\hline
EX5 & 1.188 & 0.305 \\
\hline
EX6 & 0.848 & 0.209 \\
\hline
\end{tabular}}
\end{table}
|
PMC2635613_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{4}{|l|}{\textbf{Questionnaire return}} \\
\hline
& \textbf{Incomplete for all nine months} & \textbf{Complete for all nine months} & \textbf{Incomplete for 3, 6, and 9 months} & \textbf{Complete for 3, 6, and 9 months} \\
\hline
Poor Attendance, attended less than 50\% of sessions (n = 11) & 11 (35.5\%) & 0 (0\%) & 11 (47.8\%) & 0 (0\%) \\
\hline
Good Attendance, attended 50\% or more of sessions (n = 13) & 9 (29.0\%) & 4 (44.4\%) & 3 (13\%) & 10 (58.8\%) \\
\hline
Usual Care & 11 (35.5\%) & 5 (55.6\%) & 9 (39.1\%) & 7 (41.2\%) \\
\hline
Total & 31 (100\%) & 9 (100\%) & 23 (100\%) & 17 (100\%) \\
\hline
\end{tabular}}
\end{table}
|
PMC2636800_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Protein or gene} & \textbf{Ac} & \textbf{Ad} & \textbf{Na} & \textbf{Hc} & \textbf{Ans} & \textbf{Ass} & \textbf{Tc} & \textbf{Bm} & \textbf{Di} & \textbf{Ov} \\
\hline
ATP6 & 85.9 & 85.4 & 86.9 & 78.8 & 73.3 & 74.3 & 74.8 & 19.8 & 21.7 & 21.2 \\
\hline
COX1 & 97.3 & 96.9 & 97.3 & 94.2 & 89.7 & 90.8 & 91.6 & 50.7 & 50.9 & 51.4 \\
\hline
COX2 & 89.6 & 88.3 & 92.2 & 87.4 & 79.7 & 82.7 & 81.8 & 41.4 & 41.8 & 40.5 \\
\hline
COX3 & 96.0 & 95.6 & 94.5 & 91.8 & 80.7 & 82.3 & 83.5 & 33.2 & 33.2 & 32.0 \\
\hline
CYTB & 87.0 & 87.0 & 83.7 & 79.1 & 69.4 & 73.2 & 72.4 & 53.2 & 51.6 & 53.5 \\
\hline
NAD1 & 84.4 & 84.4 & 84.8 & 74.4 & 69.3 & 69.6 & 69.5 & 48.4 & 52.3 & 50.1 \\
\hline
NAD2 & 72.5 & 71.1 & 69.7 & 50.1 & 53.5 & 48.1 & 52.2 & 35.4 & 30.8 & 35.2 \\
\hline
NAD3 & 81.9 & 81.9 & 75.6 & 67.5 & 64.8 & 67.5 & 63.9 & 38.3 & 37.5 & 39.2 \\
\hline
NAD4 & 79.2 & 79.4 & 80.6 & 69.6 & 67.4 & 65.0 & 65.0 & 45.2 & 44.4 & 44.1 \\
\hline
NAD4L & 93.5 & 93.5 & 92.2 & 65.8 & 71.4 & 68.8 & 64.9 & 30.3 & 37.5 & 33.7 \\
\hline
NAD5 & 78.5 & 77.9 & 79.1 & 67.3 & 63.2 & 64.7 & 64.5 & 42.1 & 39.1 & 39.9 \\
\hline
NAD6 & 67.3 & 70.1 & 70.8 & 48.6 & 58.3 & 57.6 & 52.7 & 27.8 & 28.4 & 29.8 \\
\hline
rrnL & 83.4 & 82.6 & 80.2 & 73.9 & 69.2 & 70.1 & 67.5 & 63.9 & 62.8 & 61.6 \\
\hline
rrnS & 86.8 & 85.6 & 86.0 & 75.6 & 74.5 & 71.2 & 70.6 & 61.1 & 61.3 & 60.5 \\
\hline
\end{tabular}}
\end{table}
|
PMC2656527_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{Age at menarche, years Odds ratio (95\% confidence interval)a, b}} \\
\hline
\\
\hline
\textbf{Tumor characteristic} & \textbf{11} & \textbf{13 $>$ 11 and} & \textbf{14 $>$ 13 and} \\
\hline
\multicolumn{4}{|l|}{Tumor size} \\
\hline
\multicolumn{4}{|l|}{1–10 mm} \\
\hline
11–20 mm & 1.00 (0.65–1.53) & 0.96 (0.74–1.25) & 1.01 (0.76–1.33) \\
\hline
21 mm & 1.05 (0.64–1.72) & 1.43 (1.06–1.92) & 1.32 (0.96–1.81) \\
\hline
\multicolumn{4}{|l|}{Grade} \\
\hline
\multicolumn{4}{|l|}{Low} \\
\hline
Medium & 2.05 (1.00–4.19) & 1.47 (1.00–2.15) & 1.74 (1.15–2.62) \\
\hline
High & 2.04 (1.01–4.16) & 1.55 (1.06–2.26) & 1.45 (1.00–2.19) \\
\hline
\multicolumn{4}{|l|}{ER status} \\
\hline
\multicolumn{4}{|l|}{Positive} \\
\hline
Negative & 1.33 (0.82–2.16) & 0.94 (0.68–1.29) & 1.15 (0.83–1.61) \\
\hline
\multicolumn{4}{|l|}{PR status} \\
\hline
\multicolumn{4}{|l|}{Positive} \\
\hline
Negative & 0.86 (0.54–1.36) & 0.99 (0.75–1.30) & 1.24 (0.93–1.66) \\
\hline
\multicolumn{4}{|l|}{Lymph node involvement} \\
\hline
\multicolumn{4}{|l|}{Absent} \\
\hline
Present & 1.49 (1.02–2.19) & 1.29 (1.02–1.65) & 1.22 (0.95–1.58) \\
\hline
\multicolumn{4}{|l|}{Histology} \\
\hline
\multicolumn{4}{|l|}{Ductal} \\
\hline
Lobular & 1.17 (0.68–2.01) & 1.08 (0.76–1.52) & 0.99 (0.68–1.43) \\
\hline
All other & 0.68 (0.39–1.18) & 1.09 (0.81–1.46) & 0.92 (0.66–1.26) \\
\hline
\end{tabular}}
\end{table}
|
PMC2656904_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Factor} & \textbf{R2} & \textbf{P-value} \\
\hline
Fasting plasma glucose & 0.0120 & NS \\
\hline
HbA1c & 0.0731 & .040 \\
\hline
Systolic blood pressure & 0.0133 & NS \\
\hline
Diastolic blood pressure & 0.0301 & NS \\
\hline
Total cholesterol (TC) & 0.0424 & NS \\
\hline
HDL-C & 0.0042 & NS \\
\hline
LDL-C & 0.0258 & NS \\
\hline
Triglyceride (TG) & 0.0588 & NS \\
\hline
Duration of diabetes & 0.0150 & NS \\
\hline
Age & 0.0367 & NS \\
\hline
BMI & 0.0174 & NS \\
\hline
Gender & 0.0151 & NS \\
\hline
\end{tabular}}
\end{table}
|
PMC2656910_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{COG id} & \textbf{Description} & \multicolumn{2}{|l|}{\textbf{Mature}} & \multicolumn{2}{|l|}{\textbf{Infant}} & \textbf{Metastat q- value} \\
\hline
& & \textbf{Mean abundance (\%)} & \textbf{stderr} & \textbf{Mean abundance (\%)} & \textbf{stderr} \\
\hline
COG0205 & 6-phosphofructokinase & 0.0017 & 0.0001 & 0.0006 & 0.0002 & 0.0313 \\
\hline
COG0358 & DNA primase (bacterial type) & 0.0024 & 0.0001 & 0.0008 & 0.0001 & 0.0072 \\
\hline
COG0507 & ATP-dependent exoDNAse (exonuclease V), alpha subunit - helicase superfamily I member & 0.0016 & 0.0001 & 0.0008 & 0.0001 & 0.0349 \\
\hline
COG0526 & Thiol-disulfide isomerase and thioredoxins & 0.0028 & 0.0002 & 0.0014 & 0.0002 & 0.0371 \\
\hline
COG0621 & 2-methylthioadenine synthetase & 0.0017 & 0.0001 & 0.0008 & 0.0002 & 0.0450 \\
\hline
COG0642 & Signal transduction histidine kinase & 0.0132 & 0.0009 & 0.0070 & 0.0004 & 0.0270 \\
\hline
COG0667 & Predicted oxidoreductases (related to aryl-alcohol dehydrogenases) & 0.0012 & 0.0001 & 0.0021 & 0.0001 & 0.0282 \\
\hline
COG0739 & Membrane proteins related to metalloendopeptidases & 0.0024 & 0.0001 & 0.0006 & 0.0001 & 0.0072 \\
\hline
COG0745 & Response regulators consisting of a CheY-like receiver domain and a winged-helix DNA-binding domain & 0.0076 & 0.0003 & 0.0051 & 0.0004 & 0.0352 \\
\hline
COG0747 & ABC-type dipeptide transport system, periplasmic component & 0.0011 & 0.0001 & 0.0027 & 0.0003 & 0.0352 \\
\hline
COG1113 & Gamma-aminobutyrate permease and related permeases & 0.0002 & 0.0001 & 0.0018 & 0.0003 & 0.0349 \\
\hline
COG1129 & ABC-type sugar transport system, ATPase component & 0.0013 & 0.0001 & 0.0028 & 0.0003 & 0.0492 \\
\hline
COG1145 & Ferredoxin & 0.0017 & 0.0001 & 0.0005 & 0.0002 & 0.0217 \\
\hline
COG1196 & Chromosome segregation ATPases & 0.0017 & 0.0001 & 0.0007 & 0.0001 & 0.0108 \\
\hline
COG1249 & Pyruvate/2-oxoglutarate dehydrogenase complex, dihydrolipoamide dehydrogenase (E3) component, and related enzymes & 0.0006 & 0.0001 & 0.0011 & 0.0001 & 0.0349 \\
\hline
COG1263 & Phosphotransferase system IIC components, glucose/maltose/N- acetylglucosamine-specific & 0.0012 & 0.0001 & 0.0031 & 0.0003 & 0.0313 \\
\hline
COG1475 & Predicted transcriptional regulators & 0.0025 & 0.0002 & 0.0014 & 0.0002 & 0.0435 \\
\hline
COG1595 & DNA-directed RNA polymerase specialized sigma subunit, sigma24 homolog & 0.0053 & 0.0004 & 0.0013 & 0.0003 & 0.0206 \\
\hline
COG1609 & Transcriptional regulators & 0.0030 & 0.0002 & 0.0092 & 0.0013 & 0.0424 \\
\hline
COG1629 & Outer membrane receptor proteins, mostly Fe transport & 0.0120 & 0.0016 & 0.0013 & 0.0007 & 0.0313 \\
\hline
COG1762 & Phosphotransferase system mannitol/fructose-specific IIA domain (Ntr-type) & 0.0004 & 0.0001 & 0.0017 & 0.0002 & 0.0293 \\
\hline
COG1961 & Site-specific recombinases, DNA invertase Pin homologs & 0.0059 & 0.0004 & 0.0018 & 0.0006 & 0.0345 \\
\hline
COG2204 & Response regulator containing CheY-like receiver, AAA-type ATPase, and DNA-binding domains & 0.0019 & 0.0002 & 0.0005 & 0.0002 & 0.0421 \\
\hline
COG2244 & Membrane protein involved in the export of O-antigen and teichoic acid & 0.0019 & 0.0001 & 0.0009 & 0.0001 & 0.0229 \\
\hline
COG2376 & Dihydroxyacetone kinase & 0.0002 & 0 & 0.0009 & 0.0001 & 0.0278 \\
\hline
COG2440 & Ferredoxin-like protein & 0 & 0 & 0.0002 & 0 & 0.0394 \\
\hline
COG2893 & Phosphotransferase system, mannose/fructose-specific component IIA & 0.0003 & 0.0001 & 0.0011 & 0.0001 & 0.0352 \\
\hline
COG3250 & Beta-galactosidase/beta-glucuronidase & 0.0056 & 0.0004 & 0.0023 & 0.0006 & 0.0435 \\
\hline
COG3451 & Type IV secretory pathway, VirB4 components & 0.0033 & 0.0001 & 0.0009 & 0.0003 & 0.0157 \\
\hline
COG3505 & Type IV secretory pathway, VirD4 components & 0.0029 & 0.0001 & 0.0010 & 0.0003 & 0.0278 \\
\hline
COG3525 & N-acetyl-beta-hexosaminidase & 0.0016 & 0.0002 & 0.0004 & 0.0001 & 0.0352 \\
\hline
COG3537 & Putative alpha-1,2-mannosidase & 0.0020 & 0.0003 & 0.0002 & 0.0002 & 0.0352 \\
\hline
COG3711 & Transcriptional antiterminator & 0.0004 & 0.0001 & 0.0020 & 0.0003 & 0.0339 \\
\hline
COG3712 & Fe2+-dicitrate sensor, membrane component & 0.0023 & 0.0003 & 0 & 0 & 0.0280 \\
\hline
COG4206 & Outer membrane cobalamin receptor protein & 0.0021 & 0.0003 & 0.0003 & 0.0001 & 0.0313 \\
\hline
COG4771 & Outer membrane receptor for ferrienterochelin and colicins & 0.0039 & 0.0005 & 0.0006 & 0.0003 & 0.0366 \\
\hline
\end{tabular}}
\end{table}
|
PMC2661018_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Saturated fatty acids} & \textbf{Linoleic acid (omega 6)} & \textbf{Total omega 3} & \textbf{Monounsaturated fatty acids} \\
\hline
Corn oila & 13 & 61 & 1 & 26 \\
\hline
Canola oila & 6 & 20 & 10 & 62 \\
\hline
n-3 supp.b & 9 & 6 & 63 & 21 \\
\hline
\end{tabular}}
\end{table}
|
PMC2669087_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{6}{|l|}{\textbf{DNA sequence identity thresholds defining a cassette-type (\%)}} \\
\hline
& \textbf{99} & \textbf{97} & \textbf{95} & \textbf{90} & \textbf{80} & \textbf{70} \\
\hline
Number of cassette-types & 3354 & 2980 & 2774 & 2389 & 2213 & 2202 \\
\hline
Shannon-Weiner Index & 7.7 & 7.5 & 7.4 & 7.1 & 6.9 & 6.9 \\
\hline
Chao-1 Estimator (Standard deviation) & 8536 (198) & 6827 (104) & 6258 (231) & 5166 (200) & 4638 (182) & 4638 (182) \\
\hline
\end{tabular}}
\end{table}
|
PMC2674596_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
Relative amount, \% & L1 & L2 & H1 & H2 & H3 \\
\hline
Human & 19.0 & 37.0 & 31.0 & 11.0 & 3.0 \\
\hline
Chimp & 22.6 & 36.6 & 25.4 & 13.2 & 2.1 \\
\hline
Dog & 23.8 & 35.5 & 23.7 & 13.4 & 3.6 \\
\hline
Overall average & 21.8 & 36.4 & 26.7 & 12.5 & 2.9 \\
\hline
Standard deviation & 2.5 & 0.8 & 3.8 & 1.3 & 0.8 \\
\hline
Chicken & 17.4 & 38.5 & 30.3 & 12.0 & (1.6)a \\
\hline
Overall average & 20.7 & 36.9 & 27.6 & 12.4 & 2.9 \\
\hline
Standard deviation & 3.0 & 1.2 & 3.6 & 1.1 & 0.8 \\
\hline
Mouse & 9.7 & 40.3 & 35.5 & 14.2 & 0.2 \\
\hline
Opossum & 49.2 & 37.9 & 10.0 & 2.3 \\
\hline
Platypus & --- & 14.5 & 71.8 & 15.1 & 0.14 \\
\hline
Zebrafish & 75.7 & 23.3 & --- & --- & --- \\
\hline
Medaka & --- & 71.0 & 23.7 & --- & --- \\
\hline
Stickleback & --- & --- & 77.5 & 21.0 & --- \\
\hline
Pufferfish & --- & --- & 55.3 & 37.8 & --- \\
\hline
\multicolumn{6}{|l|}{Average GC} \\
\hline
Human & 36.0 & 38.9 & 43.1 & 48.7 & 54.5 \\
\hline
Chimp & 36.0 & 38.9 & 43.2 & 48.6 & 55.0 \\
\hline
Dog & 35.9 & 38.9 & 43.2 & 48.7 & 55.8 \\
\hline
Mouse(b) & 36.5 & 39.4 & 43.6 & 48.1 & 54.4 \\
\hline
Platypus & --- & 40.0 & 42.9 & 47.9 & 54.9 \\
\hline
Opossum & 36.0 & 38.5 & 42.9 & 48.6 & 55.6 \\
\hline
Chicken & 36.6 & 39.3 & 43.4 & 48.8 & 54.7 \\
\hline
Zebrafish & 36.0 & 38.2 & --- & --- & --- \\
\hline
Medaka & --- & 39.9 & 42.3 & --- & --- \\
\hline
Stickleback & --- & --- & 44.2 & 47.3 & --- \\
\hline
Pufferfish & --- & --- & 44.4 & 48.2 & 54.7 \\
\hline
Overall average & 36.2 & 39.1 & 43.3 & 48.3 & 54.8 \\
\hline
Standard deviation & 0.3 & 0.6 & 0.7 & 0.5 & 0.5 \\
\hline
\multicolumn{6}{|l|}{Average size (Mb)} \\
\hline
Human & 0.90 & 0.90 & 0.80 & 0.70 & 0.70 \\
\hline
Chimp & (1.4)b & 0.80 & 0.60 & 0.70 & 0.60 \\
\hline
Dog & 1.02 & 0.69 & 0.53 & 0.55 & 0.59 \\
\hline
Mouse & 1.09 & 1.40 & 0.99 & 0.97 & 0.30 \\
\hline
Opossum & (1.6)b & 0.80 & 0.60 & 0.50 & 0.40 \\
\hline
Platypus & --- & 0.90 & 1.10 & 0.50 & --- \\
\hline
Chicken & 0.70 & 0.81 & 0.60 & 0.55 & (0.34)(a) \\
\hline
Zebrafish & (1.9)b & 0.60 & --- & --- & --- \\
\hline
Medaka & --- & (2.8)b & 0.90 & --- & --- \\
\hline
Stickleback & --- & --- & (2.1)b & 0.70 & --- \\
\hline
Pufferfish & --- & --- & 0.90 & 0.70 & --- \\
\hline
\end{tabular}}
\end{table}
|
PMC2678159_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Chemicals} & \textbf{Dm without synergists} & \textbf{Dm with PBO} & \textbf{Dm with DEF} \\
\hline
propoxur & 1.97 (1.78–2.19) & 0.27 (0.17–0.42) & 1.01 (0.83–1.24) \\
\hline
DEET & 1189 (1088–1299) & 611 (596–629) & 1078 (1005–1155) \\
\hline
mixture & 319 (296–343) & 406 (385–428) & 128 (119–136) \\
\hline
mixture ratio P:D & 1:600 & 1:2000 & 1:1000 \\
\hline
\multicolumn{4}{|l|}{Slope of the regression lines ($\pm$ s.e.)} \\
\hline
propoxur & 2.83 (0.19) & 2.16 (0.18) & 1.95 (0.22) \\
\hline
DEET & 4.16 (0.42) & 3.98 (0.12) & 3.18 (0.20) \\
\hline
mixture & 3.32 (0.18) & 3.76 (0.20) & 2.96 (0.14) \\
\hline
\end{tabular}}
\end{table}
|
PMC2680852_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Cases (n = 547) (\%)} & \textbf{Controls (n = 544) (\%)} & \textbf{ORb (95\% CI)} \\
\hline
\multicolumn{4}{|l|}{Menopausal status} \\
\hline
Premenopausal & 187 (34.2) & 230 (42.3) & 1.0 \\
\hline
Postmenopausal & 360 (65.8) & 314 (57.7) & 0.75 (0.44–1.29) \\
\hline
\multicolumn{4}{|l|}{Age at menarche} \\
\hline
$<$13 & 99 (18.1) & 87 (16.0) & 1.0 \\
\hline
13–14 & 230 (42.0) & 212 (39.0) & 0.73 (0.54–1.06) \\
\hline
$\geq$ 15 & 218 (39.9) & 245 (45.0) & 0.91 (0.62–1.26) \\
\hline
\multicolumn{4}{|l|}{Age at FFTP} \\
\hline
Nulliparous & 116 (21.2) & 65 (11.9) & 1.0 \\
\hline
$\leq$ 25 & 269 (49.2) & 296 (54.4) & 0.76 (0.52–1.09) \\
\hline
26–30 & 107 (19.6) & 138 (25.4) & 0.44 (0.30–0.65)** \\
\hline
$\geq$ 31 & 55 (10.0) & 45 (8.3) & 0.67 (0.38–1.12) \\
\hline
\multicolumn{4}{|l|}{Number of full-term pregnancies} \\
\hline
Nulliparous & 116 (21.2) & 65 (12.0) & 1.0 \\
\hline
1 & 77 (14.1) & 72 (13.2) & 0.60 (0.37–0.95)** \\
\hline
2 & 160 (29.2) & 204 (37.5) & 0.45 (0.32–0.63)* \\
\hline
3+ & 194 (35.5) & 203 (37.3) & 0.55 (0.38–0.77)* \\
\hline
\multicolumn{4}{|l|}{Use of oral contraceptives} \\
\hline
Never & 359 (65.6) & 275 (50.6) & 1.0 \\
\hline
Ever & 188 (34.4) & 269 (49.4) & 0.55 (0.40–0.71)** \\
\hline
\multicolumn{4}{|l|}{Postmenopausal use of estrogen} \\
\hline
Never & 254 (70.6) & 208 (66.2) & 1.0 \\
\hline
Ever & 106 (29.4) & 106 (33.8) & 0.80 (0.60–1.02) \\
\hline
\multicolumn{4}{|l|}{WHR} \\
\hline
$\leq$ 0.91 & 216 (39.5) & 270 (49.6) & 1.0 \\
\hline
$>$ 0.91 & 331 (60.5) & 274 (50.4) & 1.49 (1.17–1.91)** \\
\hline
\multicolumn{4}{|l|}{BMI (kg/m2)} \\
\hline
$\leq$ 25.4 & 243 (44.4) & 271 (49.8) & 1.0 \\
\hline
$>$ 25.4 & 304 (55.6) & 273 (50.2) & 1.21 (0.96–1.55) \\
\hline
\multicolumn{4}{|l|}{First-degree family history of breast cancer} \\
\hline
No & 485 (88.7) & 519 (95.4) & 1.0 \\
\hline
Yes & 62 (11.3) & 25 (4.6) & 2.63 (1.60–4.40)** \\
\hline
\multicolumn{4}{|l|}{History of benign breast disease} \\
\hline
No & 340 (62.2) & 375 (68.9) & 1.0 \\
\hline
Yes & 207 (37.8) & 169 (31.1) & 1.32 (1.02–1.72)* \\
\hline
\multicolumn{4}{|l|}{Educationa} \\
\hline
Low & 332 (60.7) & 313 (57.5) & 1.0 \\
\hline
Medium & 144 (26.3) & 153 (28.1) & 0.87 (0.66–1.15) \\
\hline
High & 71 (13.0) & 78 (14.4) & 0.83 (0.57–1.25) \\
\hline
\multicolumn{4}{|l|}{Current alcohol intake} \\
\hline
Never & 309 (56.5) & 272 (50.0) & 1.0 \\
\hline
Once a month or less & 153 (28.0) & 172 (31.6) & 0.76 (0.57–1.03) \\
\hline
Daily-weekly & 85 (15.5) & 100 (18.4) & 0.74 (0.51–1.04) \\
\hline
\multicolumn{4}{|l|}{Smoking habits} \\
\hline
Nonsmokersc & 415 (75.9) & 396 (72.8) & 1.0 \\
\hline
Ex-smokersd & 59 (10.8) & 76 (14.0) & 0.72 (0.49–1.07) \\
\hline
Current smokerse & 73 (13.3) & 72 (13.2) & 0.95 (0.66–1.38) \\
\hline
\end{tabular}}
\end{table}
|
PMC2680904_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{PON1 Q192R Premenopausal Controls, n (\%) Cases by stage Local, n (\%) OR (95\% CI)a Advanced, n (\%) OR (95\% CI)a Postmenopausal Controls, n (\%) Cases by stage Local, n (\%) OR (95\% CI)a Advanced, n (\%) OR (95\% CI)a} & \textbf{QQ 144 (62.6) 70 (63.6) 1.0 65 (84.4) 1.0 196 (62.4) 221 (96.9) 1.0 128 (96.9) 1.0} & \textbf{QR 64 (27.8) 30 (27.3) 0.96 (0.55–1.60) 11 (14.3) 0.42 (0.23–0.86) 88 (28.0) 6 (2.6) 0.06 (0.01–0.12) 3 (2.3) 0.04 (0.01–0.16)} & \textbf{RR 22 (9.6) 10 (9.1) 0.94 (0.32–2.17)b 1 (1.3) 0.23 (0.06–0.85)c 30 (9.6) 1 (0.50) 0.04 (0.00–0.23)d 1 (0.8) 0.02 (0.00–0.25)e} & \textbf{QR and RR 86 (37.4) 40 (36.4) 0.95 (0.60–1.62) 12 (15.6) 0.33 (0.14–0.60) 118 (37.6) 7 (3.1) 0.05 (0.00–0.10) 4 (3.1) 0.05 (0.01–0.11)} \\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
PON1 L55M & LL & LM & MM & LM and MM \\
\hline
\multicolumn{5}{|l|}{Premenopausal} \\
\hline
Controls, n (\%) & 78 (33.9) & 70 (30.4) & 82 (35.7) & 152 (66.1) \\
\hline
\multicolumn{5}{|l|}{Cases by stage} \\
\hline
Local, n (\%) & 16 (14.6) & 25 (22.7) & 69 (62.7) & 94 (85.4) \\
\hline
OR (95\% CI)a & 1.0 & 1.71 (0.78–2.99) & 4.12 (2.13–7.98)f & 3.05 (1.63–5.78) \\
\hline
Advanced, n (\%) & 14 (18.2) & 8 (10.4) & 55 (71.4) & 63 (81.8) \\
\hline
OR (95\% CI)a & 1.0 & 0.62 (0.22–1.70) & 3.71 (1.80–7.53)g & 2.28 (1.12–4.49) \\
\hline
\multicolumn{5}{|l|}{Postmenopausal} \\
\hline
Controls, n (\%) & 110 (35.0) & 55 (17.5) & 149 (47.5) & 204 (65.0) \\
\hline
\multicolumn{5}{|l|}{Cases by stage} \\
\hline
Local, n (\%) & 49 (21.5) & 52 (22.8) & 127 (55.7) & 179 (78.5) \\
\hline
OR (95\% CI)a & 1.0 & 2.15 (1.28–3.75) & 1.94 (1.26–2.98)h & 1.88 (1.20–2.59) \\
\hline
Advanced, n (\%) & 28 (21.2) & 30 (22.7) & 74 (56.1) & 104 (78.8) \\
\hline
OR (95\% CI)a & 1.0 & 2.16 (1.15–4.22) & 1.98 (1.19–3.36)i & 2.00 (1.18–3.29) \\
\hline
\end{tabular}}
\end{table}
|
PMC2680904_table_6
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{All patients (n)} & \textbf{Group I (n)} & \textbf{Group II (n)} \\
\hline
Total no of patients & 50 & 30 & 20 \\
\hline
Cerebral Palsy & 18 & 11 & 7 \\
\hline
Duchenne muscular dystrophy & 18 & 12 & 6 \\
\hline
Spinal muscular atrophy & 8 & 3 & 5 \\
\hline
Others & 6 & 4 & 2 \\
\hline
Thoracic curves & 9 & 6 & 3 \\
\hline
Thoraco-lumbar curves & 30 & 19 & 11 \\
\hline
Lumbar curves & 11 & 5 & 6 \\
\hline
Average age (years $\pm$ SD) & 18.1 $\pm$ 8.2 & 15.9 $\pm$ 6.5 & 24.5 $\pm$ 8.5 \\
\hline
Average Follow-up (months $\pm$ SD) & 24.9 $\pm$ 8.8 & 25.3 $\pm$ 9.1 & 23.6 $\pm$ 9.1 \\
\hline
Average Cobb angle (degree $\pm$ SD) & 79.3 $\pm$ 30.3 & 58.1 $\pm$ 15.2 & 109.9 $\pm$ 17.7 \\
\hline
Average pelvic obliquity (degree $\pm$ SD) & 14.6 $\pm$ 9.4 & 11.7 $\pm$ 8.2 & 18.7 $\pm$ 9.8 \\
\hline
Average flexibility (\%) & 29.7 $\pm$ 14.7 & 36.4 $\pm$ 14.2 & 19.9 $\pm$ 9 \\
\hline
\end{tabular}}
\end{table}
|
PMC2685769_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Profiles} & \textbf{Characterization of the cluster defining the profile} \\
\hline
Professional & contacts at work have highest median as compared to other locations: m11 = max {m1i:i = 1,…,6} \\
\hline
School & contacts at school have highest median m22 = max {m2i:i = 1,…,6} \\
\hline
Leisure & contacts during leisure activities have highest median: m33 = max {m3i:i = 1,…,6} \\
\hline
Big home & contacts at home have highest median: m44 = max {m4i:i = 1,…,6} \\
\hline
Other place & contacts in ‘‘other place’’ have highest median: m55 = max {m5i:i = 1,…,6} \\
\hline
Mixed & contacts in more than one location have a median higher than the remaining cluster: m6i.m7i for at least two i = 1,…,6. \\
\hline
Low contacts & The remaining cluster \\
\hline
\end{tabular}}
\end{table}
|
PMC2691957_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Effect} & \textbf{Pillai(df)} & \textbf{Approximate F(df)} & \textbf{P-value} \\
\hline
Age & 0.99(1) & 48.28 (25,9) & ,0.0001 \\
\hline
Experience & 0.76(1) & 1.17 (25,9) & 0.43 \\
\hline
Age*Experience & 0.87(1) & 2.46(25,9) & 0.08 \\
\hline
\end{tabular}}
\end{table}
|
PMC2702002_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{7}{|l|}{\textbf{UCP2 Genotype}} \\
\hline
& \textbf{n} & \textbf{AA} & \textbf{n} & \textbf{GA} & \textbf{n} & \textbf{GG} & \textbf{p} \\
\hline
Gender (M/F) & 140 & 102/38(72.9\%M) & 410 & 309/101(75.4\%M) & 351 & 292/59 (83.2\%M) & 0.009 \\
\hline
Age (years)* & 140 & 61.5 $\pm$ 0.94 & 410 & 62.0 $\pm$ 0.49 & 350 & 62.7 $\pm$ 057 & 0.404 \\
\hline
BMI* (kgm-2) & 92 & 27.2 $\pm$ 0.51 & 285 & 26.9 $\pm$ 0.25 & 239 & 26.4 $\pm$ 0.25 & 0.174 \\
\hline
LVEF & 113 & 47.2 $\pm$ 1.00 & 348 & 48.0 $\pm$ 0.64 & 288 & 47.9 $\pm$ 0.72 & 0.822 \\
\hline
Predischarge Mean arterial pressure (mmHg) & 133 & 82.9 $\pm$ 0.87 & 397 & 83.2 $\pm$ 0.55 & 341 & 84.6 $\pm$ 0.61 & 0.145 \\
\hline
Predischarge Systolic Blood pressure (mmHg) & 133 & 117 $\pm$ 1.28 & 397 & 116 $\pm$ 0.81 & 341 & 118 $\pm$ 0.90 & 0.163 \\
\hline
Predischarge Diastolic Blood pressure (mmHg)(mmHg) & 133 & 65.9 $\pm$ 0.82 & 397 & 66.8 $\pm$ 0.54 & 341 & 67.8 $\pm$ 0.57 & 0.176 \\
\hline
\multicolumn{8}{|l|}{History} \\
\hline
Previous myocardial infarction* & 127 & 24(18.9\%) & 389 & 72 (18.5\%) & 334 & 58 (17.4\%) & 0.896 \\
\hline
hypertension * & 129 & 47(36.4\%) & 400 & 157 (39.3\%) & 342 & 131 (38.3\%) & 0.847 \\
\hline
Type 2 Diabetes* & 139 & 22(15.8\%) & 409 & 48(11.7\%) & 349 & 38 (10.9\%) & 0.308 \\
\hline
Predischarge Atrial Fibrillation* Fibrillation* & 112 & 12(10.7\%) & 346 & 35 (10.1\%) & 297 & 47 (15.8\%) & 0.076 \\
\hline
Predischarge Ventricular Fibrillation* Fibrillation* & 113 & 11(9.7\%) & 355 & 40 11.3\%) & 300 & 21 (7.0\%) & 0.173 \\
\hline
\multicolumn{8}{|l|}{Laboratory Data} \\
\hline
Total Cholesterol* (mmol/l) & 130 & 5.94 $\pm$ 0.10 & 376 & 5.95 $\pm$ 0.065 & 330 & 5.81 $\pm$ 0.068 & 0.325 \\
\hline
HDL Cholesterol* (mmol/l) & 129 & 1.16 $\pm$ 0.026 & 371 & 1.16 $\pm$ 0.017 & 325 & 1.15 $\pm$ 0.018 & 0.913 \\
\hline
LDL Cholesterol* (mmol/l) & 97 & 3.96 $\pm$ 0.10 & 299 & 3.98 $\pm$ 0.058 & 268 & 3.83 $\pm$ 0.069 & 0.225 \\
\hline
Triglycerides* (mmol/l) & 130 & 2.02 $\pm$ 0.11 & 376 & 2.08 $\pm$ 0.096 & 330 & 2.01 $\pm$ 0.069 & 0.791 \\
\hline
($\mu$mol/l) Plasma Creatinine† & 136 & 83 (79–87) & 405 & 85 (82–87) & 347 & 85 (83–87) & 0.600 \\
\hline
Creatinine Clearance* (ml/s) & 99 & 1.28 $\pm$ 0.047 & 308 & 1.28 $\pm$ 0.023 & 267 & 1.32 $\pm$ 0.028 & 0.546 \\
\hline
Peak Creatine kinase† (units/l) & 105 & 1440(1250–1660) & 327 & 1610(1480–1740) & 269 & 1640(1510–1680) & 0.304 \\
\hline
Plasma Glucose (mmol/l) & 137 & 8.55 $\pm$ 0.27 & 404 & 8.64 $\pm$ 0.15 & 344 & 8.55 $\pm$ 0.16 & 0.912 \\
\hline
Glycated Hemoglobin \% & 105 & 6.07 $\pm$ 0.11 & 324 & 6.06 $\pm$ 0.06 & 274 & 6.03 $\pm$ 0.06 & 0.905 \\
\hline
\multicolumn{8}{|l|}{Discharge Medications} \\
\hline
ACE inhibitor * & 122 & 36(29.5\%) & 374 & 121 (32.4\%) & 318 & 109 (34.3\%) & 0.624 \\
\hline
$\beta$-blocker * & 122 & 78(63.9\%) & 374 & 232 (62.0\%) & 318 & 176 (55.3\%) & 0.119 \\
\hline
\multicolumn{8}{|l|}{Neurohormonal Data} \\
\hline
ANP (pmol/l)‡ & 138 & 26.8(24.4–29.4) & 403 & 28.5(27.0–30.0) & 346 & 28.8(27.1–30.6) & 0.406 \\
\hline
BNP (pmol/l)‡ & 138 & 18.2(16.4–20.2) & 404 & 19.8(18.7–21.0) & 346 & 19.9(18.8–21.1) & 0.290 \\
\hline
NTproBNP (pmol/l)‡ & 137 & 98.6(87.0–112) & 399 & 112(104–121) & 344 & 111(103–121) & 0.200 \\
\hline
Endothelin-1 (pmol/l)‡ & 137 & 1.64(1.52–1.77) & 398 & 1.80(1.73–1.88) & 340 & 1.76(1.167–1.81) & 0.110 \\
\hline
\end{tabular}}
\end{table}
|
PMC2702310_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Physicians (n = 900)} & \textbf{Nurses (n = 277)} \\
\hline
Percent that use dietary supplements (regularly, occasionally, or seasonally) & 72\% & 89\% \\
\hline
Percent regular users of dietary supplements & 51\% & 59\% \\
\hline
Recommend dietary supplements to patients & 79\% & 82\% \\
\hline
\end{tabular}}
\end{table}
|
PMC2714854_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Study} & \textbf{Outcome} & \textbf{Parameter estimate and 95\% confidence interval} \\
\hline
\multicolumn{3}{|l|}{Mortality 2° to COPD} \\
\hline
Ishida W, et al., Japan, 2007 [23] & Decreased mortality 2° to COPD in statin users & Inverse correlation between statin prescriptions dispensed and mortality due COPD by prefecture, p $<$ 0.0001 \\
\hline
\multicolumn{3}{|l|}{Respiratory-related urgent care} \\
\hline
Keddissi JI, et al., USA, 2007 [26] & Reduction in respiratory-related emergency- department-visits and/or hospitalizations in statin users & Incidence of respiratory related urgent care, obstructive spirometry group 0.12 $\pm$ 0.29/ patient-yrs in statin users versus 0.19 $\pm$ 0.32/ patient-yrs in control, p = 0.02 \\
\hline
\multicolumn{3}{|l|}{Lung function} \\
\hline
Keddissi JI, et al., USA, 2007 [26] & Lower decline in FEV1 and FVC/yr in statin users & Obstructive spirometry group change in FEV1 +5 $\pm$ 207 ml/yr in statin users change in FEV1–86 $\pm$ 168 ml/yr in control (p $<$ 0.0001) change in FVC +33 $\pm$ 452 ml/yr in statin users change in FVC-150 $\pm$ 328 ml/yr in control (p $<$ 0.0001) \\
\hline
Lee T-M, et al., Taiwan, 2008 [19] & No difference in pulmonary function parameters in statin users & Pravastatin group: FEV1\% at baseline 51 $\pm$ 18, at follow-up 55 $\pm$ 19 Placebo group: FEV1\% at baseline 56 $\pm$ 13, at follow-up 55 $\pm$ 14, p $>$ 0.05 \\
\hline
\multicolumn{3}{|l|}{Exercise capacity} \\
\hline
Lee T-M, et al., Taiwan, 2008 [19] & Improvement in exercise time in statin users & Pravastatin group: exercise time in s at baseline 599 $\pm$ 323, at follow-up 922 $\pm$ 328 Placebo group: exercise time in s at baseline 608 $\pm$ 273, at follow-up 609 $\pm$ 180, p $<$ 0.05 \\
\hline
\multicolumn{3}{|l|}{Borg dyspnea score after exercise tests} \\
\hline
Lee T-M, et al., Taiwan, 2008 [19] & Lesser degree of dyspnea after exercise in statin users & Pravastatin group: Borg dyspnea score at baseline 7.0 $\pm$ 0.8, at follow-up 4.0 $\pm$ 0.7 Placebo group: Borg dyspnea score at baseline 6.9 $\pm$ 0.8, at follow-up 6.9 $\pm$ 1.0, p $<$ 0.05 \\
\hline
\multicolumn{3}{|l|}{CRP/IL-6 levels} \\
\hline
Lee T-M, et al., Taiwan, 2008 [19] & Decrease in CRP/IL-6 levels in statin users & Pravastatin group: CRP (mg/l) at baseline 3.94 $\pm$ 3.54, at follow-up 3.85 $\pm$ 2.56 Placebo group: CRP (mg/l) at baseline 4.06 $\pm$ 2.67, at follow-up 2.66 $\pm$ 2.49, p $<$ 0.05 \\
\hline
\end{tabular}}
\end{table}
|
PMC2716302_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
Age (years) & 62 $\pm$ 18 (19 to 100) \\
\hline
Female/male & 83/97 \\
\hline
SAPS II & 37 $\pm$ 18 (9 to 103) \\
\hline
Mortality & 19\% (35 out of 180 patients) \\
\hline
Cirrhosis & 6 \\
\hline
Cancer & 45 \\
\hline
Community-acquired/postoperative peritonitis & 112/68 \\
\hline
\end{tabular}}
\end{table}
|
PMC2717471_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Known}} & \multicolumn{2}{|l|}{\textbf{Unknown}} \\
\hline
\textbf{Category*} & \textbf{Duplicated} & \textbf{Retrotransposed} & \textbf{Single-exon pseudogene} & \textbf{Multi-exon pseudogne} \\
\hline
Unsupported & 507 & 162 & 453 & 69 \\
\hline
Long UTR & 62 & 11 & 25 & 6 \\
\hline
Short CDS & 1 & 0 & 4 & 0 \\
\hline
Poly-A tail & 9 & 2 & 16 & 3 \\
\hline
Segmentally duplicated & 36 & 2 & 1 & 1 \\
\hline
Single-exon singletons & 39 & 34 & 115 & 14 \\
\hline
Total (non redundant) & 627 & 189 & 539 & 84 \\
\hline
\end{tabular}}
\end{table}
|
PMC2724416_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Fibromyalgia} & \textbf{RA/SLE} & \textbf{Major depressiona} & \textbf{Healthy controls} \\
\hline
Number analyzed & 202 & 51 & 11 & 213 \\
\hline
Age, years & 51 $\pm$ 10.5 & 49 $\pm$ 13.1a & 46 $\pm$ 11.4b & 43 $\pm$ 14.0c \\
\hline
Gender ratio, female/male & 16/1 & ND & 5 $\pm$ 1 & 13 $\pm$ 1 \\
\hline
Number of pain locations & 16 $\pm$ 4.9 & 7.0 $\pm$ 4.4 & 4.0 $\pm$ 2.5 & 1.6 $\pm$ 2.3 \\
\hline
\end{tabular}}
\end{table}
|
PMC2745803_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Diana-microT} & \textbf{PicTar} & \textbf{TargetScan 4.2} \\
\hline
Diana-microT & 22391 & 8882 & 10651 \\
\hline
PicTar & & 17135 & 12902 \\
\hline
TargetScan 4.2 & & & 19299 \\
\hline
\end{tabular}}
\end{table}
|
PMC2752464_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Treatment Comparison} & \multicolumn{2}{|l|}{\textbf{Mixed Treatment Comparison}} & \multicolumn{2}{|l|}{\textbf{Adjusted Indirect Comparison}} \\
\hline
& \textbf{Odds Ratio} & \textbf{95\% Credible Interval} & \textbf{Odds Ratio} & \textbf{95\% Confidence Interval} \\
\hline
Fluconazole vs. Control & 0.81 & (0.48, 1.37) & 0.94 & (0.54, 1.63) \\
\hline
Itraconazole vs. Control & 0.90 & (0.41, 1.99) & 0.49 & (0.15, 1.56) \\
\hline
Liposomal Amphotericin B vs. Control & 0.50 & (0.09, 2.33) & 0.54 & (0.10, 2.52) \\
\hline
Ketoconazole vs. Control & 1.83 & (0.38, 8.93) & 1.66 & (0.41, 6.66) \\
\hline
Intraconazole vs. Fluconazole & 1.12 & (0.52, 2.41) & 1.69 & (0.58, 5.33) \\
\hline
Liposomal Amphotericin B vs. Fluconazole & 0.62 & (0.10, 3.17) & 0.57 & (0.09, 3.39) \\
\hline
Ketoconazole vs. Fluconazole & 2.27 & (0.43, 12.09) & 1.76 & (0.39, 7.94)*** \\
\hline
Liposomal Amphotericin B vs. Itraconazole & 0.55 & (0.09, 3.11) & 1.10 & (0.14, 8.65)**, *** \\
\hline
Ketoconazole vs. Itraconazole & 2.03 & (0.35, 11.87) & 3.38 & (0.54, 21.16)*** \\
\hline
Ketoconazole vs. Liposomal Amphotericine B & 3.68 & (0.41, 35.30) & 3.07 & (0.34, 27.48)*** \\
\hline
\end{tabular}}
\end{table}
|
PMC2760541_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Rs10954213} & \multicolumn{2}{|l|}{\textbf{Allele}} & \multicolumn{3}{|l|}{\textbf{Genotype}} \\
\hline
\textbf{Group} & \textbf{A} & \textbf{G} & \textbf{AA} & \textbf{AG} & \textbf{GG} \\
\hline
BPD & 129 & 153 & 33 & 63 & 45 \\
\hline
C & 183 & 197 & 44 & 95 & 51 \\
\hline
MDD & 8 & 6 & 1 & 6 & 0 \\
\hline
SZ & 100 & 96 & 25 & 50 & 23 \\
\hline
\end{tabular}}
\end{table}
|
PMC2760574_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Genome/$\Delta$ bit score to 2nd hit1} & \textbf{R2} & \textbf{P} & \textbf{$\Delta$ $\sigma$ Heterokont} & \textbf{$\Delta$ $\sigma$ Reds} \\
\hline
P. ramorum/5\% & 0.714 & 0.007 & 2.71 & -0.12 \\
\hline
P. sojae/5\% & 0.717 & 0.007 & 2.67 & -0.15 \\
\hline
P. ramorum/10\% & 0.629 & 0.019 & 2.75 & -0.16 \\
\hline
P. sojae/10\% & 0.644 & 0.016 & 2.72 & -0.18 \\
\hline
\end{tabular}}
\end{table}
|
PMC2770532_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{(mV) Mean Amplitude (300–800 ms)}} & \multicolumn{2}{|l|}{\textbf{(mV) Peak Amplitude (jackknifed values)}} & \multicolumn{2}{|l|}{\textbf{Peak Latency (ms) (jackknifed values)}} \\
\hline
\textbf{Condition} & \textbf{M} & \textbf{SE} & \textbf{M} & \textbf{SE} & \textbf{M} & \textbf{SE} \\
\hline
Target Present Search & 21.33 & 0.40 & 22.20 & 0.06 & 704 & 0.5 \\
\hline
Target Absent Search & 21.15 & 0.25 & 21.90 & 0.03 & 680 & 0.6 \\
\hline
Change Detection & 21.43 & 0.32 & 21.96 & 0.05 & 536 & 9.4 \\
\hline
\end{tabular}}
\end{table}
|
PMC2777337_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{PCT test} & \textbf{Cutoff 0.5 ng /mL} & \textbf{Cutoff 2.0 ng/mL} & \textbf{Cutoff 10 ng/mL} \\
\hline
Sensitivity & 0.52 [0.37–0.67] & 0.20 [0.10–0.34] & 0.02 [0.00–0.13] \\
\hline
Specificity & 0.76 [0.66–0.83] & 0.91 [0.84–0.95] & 0.97 [0.92–0.99] \\
\hline
Positive predictive value & 0.47 [0.33–0.61] & 0.47 [0.25–0.71] & 0.25 [0.01–0.78] \\
\hline
Negative predictive value & 0.79 [0.70–0.86] & 0.73 [0.65–0.80] & 0.71 [0.63–0.78] \\
\hline
\end{tabular}}
\end{table}
|
PMC2792948_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Factor 1 Perceived susceptibility} & \textbf{Factor 2 Perceived severity} \\
\hline
\\
\hline
Adolescent alcohol use outside home & 0.834 & 0.182 \\
\hline
Worries about adolescent alcohol use & 0.843 & 0.104 \\
\hline
Approved age for alcohol use & 0.085 & 0.657 \\
\hline
Adolescents have been offered alcohol at home & -0.165 & -0.731 \\
\hline
Parents' opinion about adolescents' alcohol use & -0.112 & -0.714 \\
\hline
\end{tabular}}
\end{table}
|
PMC2809065_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Parameter} & \textbf{Coefficient} & \textbf{Standard error} & \textbf{95\% Wald CI} & \textbf{P value} \\
\hline
(Intercept) & 6.816 & 0.0386 & 6.740 - 6.891 & $<$ 0.001 \\
\hline
Year 2009 & -3.907 & 0.2034 & -4.306 - -3.508 & $<$ 0.001 \\
\hline
Year 2008 & -4.405 & 0.2598 & -4.914 - -3.895 & $<$ 0.001 \\
\hline
Year 2007 & -3.085 & 0.1365 & -3.353 - -2.818 & $<$ 0.001 \\
\hline
Year 2006 & -2.721 & 0.1149 & -2.946 - -2.496 & $<$ 0.001 \\
\hline
Year 2005 & -0.948 & 0.0540 & -1.054 - -0.842 & $<$ 0.001 \\
\hline
Year 2004 & -0.483 & 0.0462 & -0.574 - -0.393 & $<$ 0.001 \\
\hline
Year 2003 & a 0 \\
\hline
Pregnancy & -2.530 & 0.1196 & -2.765 - -2.296 & $<$ 0.001 \\
\hline
5 years old $\geqq$ & 0.532 & 0.0409 & 0.452 - 0.612 & $<$ 0.001 \\
\hline
$<$5 years old & a 0 \\
\hline
(Scale) & b 2.068 \\
\hline
\end{tabular}}
\end{table}
|
PMC2823607_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Isolated nurses (n = 103)} & \textbf{Non-isolated nurses (n = 94)} & \textbf{p value} \\
\hline
\multicolumn{4}{|l|}{Age categories (years)} \\
\hline
20 - 39 & 18 (17.5) & 24 (26.1) & Chi-square test for trend = 0.176, df = 1, p = 0.675. \\
\hline
40 - 49 & 57 (55.3) & 39 (42.4) \\
\hline
50 and above & 28 (27.2) & 29 (31.5) \\
\hline
\multicolumn{4}{|l|}{Grade} \\
\hline
D, E or F & 7 (7.1) & 8 (8.7) & Chi-square test for trend = 2.350, df = 1, p = 0.125. \\
\hline
G & 79 (80.6) & 61 (66.3) \\
\hline
H & 12 (12.2) & 23 (25.0) \\
\hline
\multicolumn{4}{|l|}{Practice list size} \\
\hline
Up to 2000 patients & 12 (12.1) & 5 (5.6) & Chi-square test for trend = 5.107, df = 1, p = 0.024. \\
\hline
2001 - 4000 & 30 (30.3) & 18 (20.2) \\
\hline
4001 - 6000 & 24 (24.2) & 29 (32.6) \\
\hline
6001 - 8000 & 15 (15.2) & 12 (13.5) \\
\hline
8001 - 10,000 & 12 (12.1) & 14 (15.7) \\
\hline
Over 10,000 patients & 6 (6.1) & 11 (12.4) \\
\hline
\multicolumn{4}{|l|}{Number of practice nurses in the team} \\
\hline
1 & 40 (38.8) & 21 (22.8) & Chi-square test for trend = 8.847, df = 1, p = 0.003. \\
\hline
2 & 44 (42.7) & 39 (42.4) \\
\hline
3 or more & 19 (18.4) & 32 (34.8) \\
\hline
\end{tabular}}
\end{table}
|
PMC2823612_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{[days]◆: Time} & & \textbf{0} & \textbf{28} & \textbf{35} \\
\hline
Treatment group & Animal \\
\hline
Vaccinated & V1 & 0.057* & 0.185 & 0.736 \\
\hline
& V2 & 0.056 & 0.267 & 0.476 \\
\hline
& V3 & 0.054 & & 0.223 \\
\hline
& V4 & 0.051 & 0.121 & 0.542 \\
\hline
& V5 & 0.052 & 0.054 & 0.408 \\
\hline
& Average# & 0.054a & 0.157a & 0.477a \\
\hline
Unvaccinated & C1 & 0.055 & 0.059 & 0.099 \\
\hline
& C2 & 0.052 & 0.060 & 0.214 \\
\hline
& C3 & 0.056 & 0.055 & 0.106 \\
\hline
& C4 & 0.057 & 0.060 & 0.067 \\
\hline
& Average & 0.055a & 0.059a & 0.121b \\
\hline
\end{tabular}}
\end{table}
|
PMC2824702_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{IL-2} & \textbf{IL-2+ART} & \textbf{Control} & \textbf{Total} \\
\hline
\multicolumn{5}{|l|}{Age (years)} \\
\hline
Median & 35 & 35 & 36 & 36 \\
\hline
Interquartile range & & & & 30–44 \\
\hline
Gender (\% female) & 19.1 & 14.9 & 17.6 & 17.2 \\
\hline
\multicolumn{5}{|l|}{Race (\%)} \\
\hline
Asian & 24.7 & 26.4 & 24.2 & 25.1 \\
\hline
Black & 4.5 & 4.6 & 8.8 & 6.0 \\
\hline
White/other & 70.8 & 69.0 & 67.0 & 68.9 \\
\hline
\multicolumn{5}{|l|}{CD4+ (cells/mm3) count} \\
\hline
Median & 399 & 425 & 432 & 419 \\
\hline
Interquartile range & & & & 359–512 \\
\hline
\multicolumn{5}{|l|}{HIV-RNA (copies)} \\
\hline
Median & 23,508 & 21,881 & 24,328 & 22,384 \\
\hline
Interquartile range & & & & 7,189–61,169 \\
\hline
\multicolumn{5}{|l|}{Medication Use and History} \\
\hline
Antiretroviral (ART) naı¨ve (\%) & 76.4 & 87.4 & 72.5 & 78.7 \\
\hline
Months since last ART use* (median) & 36.9 & 28.9 & 32.0 & 21.3 \\
\hline
Current OI prophylaxis use (\%) & 3.4 & 2.3 & 2.2 & 2.6 \\
\hline
\multicolumn{5}{|l|}{Likely mode of HIV transmission** (\%)} \\
\hline
Person of same sex & 60.7 & 56.3 & 61.5 & 59.6 \\
\hline
Person of opposite sex & 38.2 & 41.4 & 37.4 & 39.0 \\
\hline
Injection drug use & 2.2 & 4.6 & 0.0 & 2.2 \\
\hline
Blood products & 1.1 & 1.1 & 0.0 & 0.7 \\
\hline
Other or unknown & 2.2 & 2.3 & 2.2 & 2.2 \\
\hline
\multicolumn{5}{|l|}{Hepatitis Status (\%)} \\
\hline
Hepatitis B surface antigen positive & 5.6 & 0.0 & 5.6 & 3.8 \\
\hline
Hepatitis C antibody positive & 5.7 & 5.7 & 7.8 & 6.4 \\
\hline
\multicolumn{5}{|l|}{(kg/m2) BMI} \\
\hline
Median & 23.5 & 23.2 & 23.6 & 23.4 \\
\hline
Interquartile range & & & & 21.2–26.2 \\
\hline
\multicolumn{5}{|l|}{Total cholesterol (mg/dl)} \\
\hline
Median & 166 & 170 & 170 & 170 \\
\hline
Interquartile range & & & & 147–196 \\
\hline
\end{tabular}}
\end{table}
|
PMC2826395_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Gene} & \textbf{Coverage} & \textbf{#G} & \textbf{#A} & \textbf{Freq. of G} & \textbf{aa change} \\
\hline
Gabra3 & 679 & 631 & 48 & 92.93\% & I/M \\
\hline
Elavl2 & 633 & 9 & 624 & 1.422\% & I/V \\
\hline
Elavl2 & 625 & 15 & 610 & 2.400\% & N/D \\
\hline
Elavl4 & 443 & 4 & 439 & 0.903\% & 3' UTR \\
\hline
Elavl4 & 462 & 3 & 459 & 0.649\% & 3' UTR \\
\hline
Elavl4 & 220 & 2 & 218 & 0.909\% & T/A \\
\hline
Matr3 & 220 & 3 & 217 & 1.364\% & R/G \\
\hline
Stk22c & 209 & 2 & 207 & 0.957\% & D/G \\
\hline
Ube1x & 349 & 3 & 346 & 0.860\% & I/M \\
\hline
Xpo7 & 390 & 3 & 387 & 0.769\% & D/G \\
\hline
Hnrph2 & 265 & 2 & 263 & 0.755\% & K/E \\
\hline
\end{tabular}}
\end{table}
|
PMC2831006_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{E. chaffeensis protein} & \textbf{OM (Da)} & \textbf{PM (Da)} & \textbf{MS (Da)} & \textbf{Mass difference (OM-PM in Da)} & \textbf{Mass difference (PM-MS in Da)} \\
\hline
Native TRP47 & ,47,000 & 32,925.5 & 33,104.5 & 14,075 & 179 \\
\hline
Native TRP32 & ,32,000 & 22,449.0 & 22,736.8 & 9,550 & 288 \\
\hline
GST-TRP47 & ,67,000 & 56,581.6 & 56,698.0 & 10,418 & 116 \\
\hline
GST-NterTRP47 & ,42,000 & 41,580.6 & ND & 419 & ND \\
\hline
GST-CterTRP47 & ,55,000 & 43,525.4 & 43,522.0 & 11,474 & 3 \\
\hline
\end{tabular}}
\end{table}
|
PMC2832021_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Initial 3 months (n = 583 individuals)} & & \textbf{After 3 months (n = 559 individuals)} \\
\hline
Variable & Unadjusted Hazard Ratio (95\% CI) & Adjusted Hazard Ratio (95\% CI) & Unadjusted Hazard Ratio (95\% CI) & Adjusted Hazard Ratio (95\% CI) \\
\hline
Age (years) & 0.99 (0.95-1.04) & 0.87 (0.79-0.96) & 0.98 (0.95-1.10) & N/S \\
\hline
\multicolumn{5}{|l|}{Sex;} \\
\hline
Female & REF & & REF \\
\hline
Male & 4.17 (1.83-.54) & 9.55 (2.35-38.78) & 0.59 (0.30-1.16) & 0.55 (0.27-1.10) \\
\hline
Log10 HIV RNA & 1.85 (0.86-3.97) & 2.69 (1.11-6.51) & 0.83 (0.59-1.13) & N/S \\
\hline
Transfer in & 0.99 (0.13-7.30) & N/S & 0.38 (0.05-2.78) & N/S \\
\hline
Log10 CD4 & 1.35 (0.78-2.40) & 2.02 (0.58-4.76) & 0.83 (0.65-1.07) & 0.87(0.67-1.13) \\
\hline
\multicolumn{5}{|l|}{Prior TB;} \\
\hline
No & REF & & REF \\
\hline
Yes & 1.42 (0.63-3.20) & 1.16 (0.33-4.03) & 1.77 (1.04-2.98) & 1.32 (0.73-2.38) \\
\hline
\multicolumn{5}{|l|}{WHO stage} \\
\hline
1 or 2 & REF & & REF \\
\hline
3 or 4 & 2.33 (0.92-5.92) & N/S & 2.11 (1.15-3.87) & 1.94 (0.99-3.38) \\
\hline
Unknown & 0.40 (0.05-3.32) & N/S & 1.27 (0.52-3.12) & 1.43 (0.58-3.56) \\
\hline
\end{tabular}}
\end{table}
|
PMC2835706_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Variable} & \textbf{No. (\%)} \\
\hline
Mortality & 1 (1.7) \\
\hline
Myocardial infarction & 1 (1) \\
\hline
Target vessel reintervention & 4 (6) \\
\hline
Reoperation for bleeding & 2 (3) \\
\hline
Pleural effusion & 2 (3) \\
\hline
Pulmonary infection & 2 (3) \\
\hline
Post cardiotomy syndrome & 1 (1) \\
\hline
\end{tabular}}
\end{table}
|
PMC2842890_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Subscale} & \textbf{Patients 7 years postoperative (n = 151)} & \textbf{Reference group 7 years Postoperative (n = 65)} & \textbf{p-value} \\
\hline
SF-36 PF & 54 (27.2) & 69 (31.3) & 0.01 \\
\hline
SF-36 RP & 45 (44.6) & 60 (46.0) & 0.05 \\
\hline
SF-36 BP & 63 (28.1) & 69 (26.9) & 0.19 \\
\hline
SF-36 GH 10 & 63 (22.4) & 62 (25.0) & 0.94 \\
\hline
SF-36 VT & 59 (46.4) & 72 (43.0) & 0.05 \\
\hline
SF-36 SF the & 62 (23.8) & 65 (21.8) & 0.36 \\
\hline
SF-36 RE & 81 (23.2) & 79 (24.7) & 0.53 \\
\hline
SF-36 MH (Fig- & 79 (19.1) & 72 (43.0) & 0.90 \\
\hline
WOMAC pain the & 86 (16.5) & 91 (18.2) & 0.05 \\
\hline
WOMAC stiffness 7-year & 78 (22.1) & 89 (20.0) & $<$0.001 \\
\hline
WOMAC function & 76 (21.1) & 73 (23.8) & 0.56 \\
\hline
\end{tabular}}
\end{table}
|
PMC2847954_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{(A) A DNA database.}} \\
\hline
\multicolumn{2}{|l|}{CCCTAATG} \\
\hline
\multicolumn{2}{|l|}{TTAATAAT} \\
\hline
\multicolumn{2}{|l|}{ATAATGCG} \\
\hline
\multicolumn{2}{|l|}{(B) All 5-patterns in the database.} \\
\hline
\multicolumn{2}{|l|}{CCCTA, CCTAA, CTAAT, TAATG, TTAAT, TAATA} \\
\hline
\multicolumn{2}{|l|}{AATAA, ATAAT, ATAAT, TAATG, AATGC, ATGCG} \\
\hline
\multicolumn{2}{|l|}{(C) Some unique signatures in the database.} \\
\hline
$\Omega$5,1 & CCCTA, CCTAA, AATAA, AATGC, ATGCG \\
\hline
$\Omega$5,2 & ATGCG \\
\hline
$\Omega$4,1 & CCCT, CCTA, ATGC, TGCG \\
\hline
$\Omega$4,2 & TGCG \\
\hline
\end{tabular}}
\end{table}
|
PMC2848650_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\multicolumn{3}{|l|}{= Total number of 16-year-olds in the city of Uppsala: n 2,465} \\
\hline
\multicolumn{3}{|l|}{= Participated in the screening procedure: n 2,300} \\
\hline
\multicolumn{3}{|l|}{= Delivered complete screening questionnaires: n 2,270} \\
\hline
& Selected due to high scores on the Beck Depression Inventory (BDI) or Center for Epidemiological Studies scale (CES) or had attempted suicide & Selected as controls \\
\hline
Selected for interview & = n 355 & = n 355 \\
\hline
Interviewed (structured interview by means of DICA) & n = 314 & n = 317 \\
\hline
Refused to participate in follow up & = n 6 & = n 10 \\
\hline
Interviewed and willing to participate in follow-up & = n 308 & = n 307 \\
\hline
Depressed at DICA interview & & = n 55 \\
\hline
& Depressed at screening or at interview or = n having at least one suicide attempt: 363 & Controls (not depressed at screening or interview and without any suicide attempt): = n 252 \\
\hline
Incomplete personal identification nr & = n 1 & = n 2 \\
\hline
Included in follow-up & = n 362 & = n 250 \\
\hline
Men/Women & 80/282 & 56/194 \\
\hline
Age at follow up, years & 31.6 $\pm$ 0.7 & 31.6 $\pm$ 0.6 \\
\hline
Major depression at first investigation Females/Males & 213/48 \\
\hline
Dysthymia and sub-syndromal depression at first investigation Females/Males & 70/31 \\
\hline
\end{tabular}}
\end{table}
|
PMC2853351_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Compd} & \textbf{R1} & \textbf{R2} & \textbf{R3} & \textbf{TryR [mm] IC50} \\
\hline
39 & Me & Me & 4’-Methylphenyl & 8.6 \\
\hline
40 & Me & CH2CH3 & Thiophen-2-yl & 12.8 \\
\hline
41 & Me & CH2CH3 & 2’-Fluoro-5’-Bromophenyl & 10.2 \\
\hline
42 & Me & H & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
43 & H & H & 2’-Fluoro-5’-Bromophenyl & 92 \\
\hline
44 & Me & CH2CH3 & Pyridine-3-yl & $>$100 \\
\hline
45 & Me & CH2CH3 & 4’-Bromothiophen-2-yl & 13.0 \\
\hline
46 & Me & CH2CH3 & 4’-Trifluoromethylphenyl & 15.2 \\
\hline
47 & Me & CH2CH3 & Phenyl & 11.3 \\
\hline
48 & Me & CH2CH2NMe2 & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
49 & Me & CH2CH3 & CH=CHC6H5 & 2.6 \\
\hline
50 & Me & CH(CH3)2 & 2’-Fluoro-5’-Bromophenyl & $>$50 \\
\hline
51 & Me & (CH2)3CH3 & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
52 & Me & cyclopentyl & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
\end{tabular}}
\end{table}
|
PMC2855869_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& & \multicolumn{2}{|l|}{\textbf{TeleAtlas}} & \multicolumn{2}{|l|}{\textbf{ArcView/NAVTEQ}} \\
\hline
\textbf{Address status} & \textbf{N} & \textbf{Error1} & \textbf{N (\%)2} & \textbf{Error1} & \textbf{N (\%)2} \\
\hline
Self-reported Post-E911 Street & 71 & 132 (75, 309) & 52 (73\%) & 40 (17, 70) & 70 (99\%) \\
\hline
Self-reported Pre-E911 Street & 37 & 243 (117, 418) & 34 (92\%) & 236 (153, 413) & 29 (78\%) \\
\hline
Total Addresses3 & 135 & 174 (81, 357) & 86 (64\%) & 62 (25, 151) & 99 (73\%) \\
\hline
\end{tabular}}
\end{table}
|
PMC2867955_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Clinical group} & \textbf{Controls (n = 27)} & \textbf{Not Infected (n = 118)} & \textbf{Infected (n = 74)} \\
\hline
& & & & Culture positive (n = 41) & Culture Negative (n = 33) \\
\hline
Duration of antibiotic therapy (days) & 0 (0,0) & 2 (1,3) & 5 (5,7) & 7 (5,7) & 5 (5,7) \\
\hline
sICAM-1 (ng/ml), & 165 (130,290) & 168 (140,228) & 341 (236,554) P $<$ 0.001 & 405 (252,666) P $<$ 0.001 & 306 (230,484) P $<$ 0.001 \\
\hline
hsCRP(mg/l), & 0.1 (0.1,0.4) & 0.1 (0.1,0.7) & 0.85 (0.3,15.9) P $<$ 0.001 & 2.0 (0.7,21.2) P $<$ 0.001 & 0.45 (0.1,2.2) P = 0.012 \\
\hline
SAA(mg/l) & 0.9 (0.9,1.0) & 1.0 (0.9,2.0) & 1.5 (0.9,5.8) P = 0.004 & 2.0 (1.0-10.0) P = 0.001 & 1.0 (0.9,2.0) P $>$ 0.05 \\
\hline
sE-selectin(ng/ml) & 71 (51,118) & 90 (59,124) & 135 (94,192) P $<$ 0.001 & 158 (94,207) P $<$ 0.001 & 109 (92,184) P = 0.009 \\
\hline
\end{tabular}}
\end{table}
|
PMC2868836_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Theme} & \textbf{Descriptive terms (reference)} \\
\hline
Methods that support sustainable development & Health Impact Assessment as a method for promoting health and sustainability. Use of sustainability appraisal approach—‘Spectrum’, designed to integrated health and sustainability agendas with participatory process. Outline provided of six-stage appraisal process.54 Health Impact Pathways as a method of assessing the potential impacts and vulnerabilities of climate change hazards at different points in time with examples of response mechanisms.55 government initiatives such as Health Action Zones and Healthy Cities programmes provide opportunities for addressing sustainable development and building resilience.56 \\
\hline
Governance and attitude/behaviour change & Example of multi-disciplinary approach to water treatment and water quality based on recommendations from the World Humanity Action Trust.57 Links between attitudes and perceptions of recycling behaviour at home and at work,58 do not necessarily translate into recycling behaviour.59 strategies are suggested for improving behaviour.59 \\
\hline
Gardening and Food & sourcing food locally to reduce food miles.25,60 Food co-operatives and community agriculture, partnerships with farmers to promote local growing, improving supply of fruit to schools.56 Community gardens could act as a model for the implementation of social, economic and environmental policies at local level.61 \\
\hline
energy saving/Waste Management & Affordable warmth programme, sustainable buildings.56 Energy saving equipment for heating and ventilation.60 Combined heat and power plant and energy efficiency measures.62 Wind turbines and solar panels installed.25 reusable nappies reduce clinical waste.25 \\
\hline
Transport & green travel plans.25,60 \\
\hline
\end{tabular}}
\end{table}
|
PMC2872568_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{All oligo arrays (service)} & \textbf{Oligo arrays following normal karyotype} & \textbf{Oligo arrays as first line test} \\
\hline
Total patients & 2414 & 1245 & 1169 \\
\hline
Abnormal patients & 585 (24\%) & 325 (26\%) & 260 (22\%) \\
\hline
- inherited & 169 & 97 & 72 \\
\hline
- de novo & 63 & 52 & 11 \\
\hline
- unknown inheritance & 353 & 176 & 177 \\
\hline
\end{tabular}}
\end{table}
|
PMC2885406_table_2
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 2